Online ISSN : 2249-4618 Print ISSN : 0975-5888 DOI : 10.17406/GJMRA

# GLOBAL JOURNAL

OF MEDICAL RESEARCH: J

# Dentistry & Otolaryngology



Retrospective Radiographic Study

**Highlights** 

Oral Complications in Cancer Patients

**Discovering Thoughts, Inventing Future** 

**VOLUME 24** 

ISSUE 1

VERSION 1.0



# Global Journal of Medical Research: J Dentistry & Otolaryngology

## Global Journal of Medical Research: J Dentistry & Otolaryngology

VOLUME 24 ISSUE 1 (VER. 1.0)

# © Global Journal of Medical Research. 2024.

All rights reserved.

This is a special issue published in version 1.0 of "Global Journal of Medical Research." By Global Journals Inc.

All articles are open access articles distributed under "Global Journal of Medical Research"

Reading License, which permits restricted use. Entire contents are copyright by of "Global Journal of Medical Research" unless otherwise noted on specific articles.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without written permission.

The opinions and statements made in this book are those of the authors concerned.

Ultraculture has not verified and neither confirms nor denies any of the foregoing and no warranty or fitness is implied.

Engage with the contents herein at your own risk

The use of this journal, and the terms and conditions for our providing information, is governed by our Disclaimer, Terms and Conditions and Privacy Policy given on our website <a href="http://globaljournals.us/terms-and-condition/">http://globaljournals.us/terms-and-condition/</a>

menu-id-1463/

By referring / using / reading / any type of association / referencing this journal, this signifies and you acknowledge that you have read them and that you accept and will be bound by the terms thereof.

All information, journals, this journal, activities undertaken, materials, services and our website, terms and conditions, privacy policy, and this journal is subject to change anytime without any prior notice.

Incorporation No.: 0423089 License No.: 42125/022010/1186 Registration No.: 430374 Import-Export Code: 1109007027 Employer Identification Number (EIN): USA Tax ID: 98-0673427

### Global Journals Inc.

(A Delaware USA Incorporation with "Good Standing"; Reg. Number: 0423089)
Sponsors: Open Association of Research Society
Open Scientific Standards

### Publisher's Headquarters office

Global Journals® Headquarters 945th Concord Streets, Framingham Massachusetts Pin: 01701, United States of America USA Toll Free: +001-888-839-7392

USA Toll Free: +001-888-839-7392 USA Toll Free Fax: +001-888-839-7392

### Offset Typesetting

Global Journals Incorporated 2nd, Lansdowne, Lansdowne Rd., Croydon-Surrey, Pin: CR9 2ER, United Kingdom

### Packaging & Continental Dispatching

Global Journals Pvt Ltd E-3130 Sudama Nagar, Near Gopur Square, Indore, M.P., Pin:452009, India

## Find a correspondence nodal officer near you

To find nodal officer of your country, please email us at *local@globaljournals.org* 

#### *eContacts*

Press Inquiries: press@globaljournals.org
Investor Inquiries: investors@globaljournals.org
Technical Support: technology@globaljournals.org
Media & Releases: media@globaljournals.org

### Pricing (Excluding Air Parcel Charges):

Yearly Subscription (Personal & Institutional) 250 USD (B/W) & 350 USD (Color)

#### EDITORIAL BOARD

#### GLOBAL JOURNAL OF MEDICAL RESEARCH

#### Dr. Apostolos Ch. Zarros

DM, Degree (Ptychio) holder in Medicine,
National and Kapodistrian University of Athens
MRes, Master of Research in Molecular Functions in
Disease, University of Glasgow FRNS, Fellow, Royal
Numismatic Society Member, European Society for
Neurochemistry Member, Royal Institute of Philosophy
Scotland, United Kingdom

#### Dr. Alfio Ferlito

Professor Department of Surgical Sciences University of Udine School of Medicine, Italy

### Dr. Jixin Zhong

Department of Medicine, Affiliated Hospital of Guangdong Medical College, Zhanjiang, China, Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH 43210, US

#### Rama Rao Ganga

**MBBS** 

MS (Universty of Health Sciences, Vijayawada, India) MRCS (Royal Coillege of Surgeons of Edinburgh, UK) United States

#### Dr. Izzet Yavuz

MSc, Ph.D., D Ped Dent.

Associate Professor, Pediatric Dentistry Faculty of Dentistry, University of Dicle Diyarbakir, Turkey

### Sanguansak Rerksuppaphol

Department of Pediatrics Faculty of Medicine Srinakharinwirot University NakornNayok, Thailand

### Dr. William Chi-shing Cho

Ph.D.,

Department of Clinical Oncology Queen Elizabeth Hospital Hong Kong

### Dr. Michael Wink

Ph.D., Technical University Braunschweig, Germany
Head of Department Institute of Pharmacy and Molecular
Biotechnology, Heidelberg University, Germany

### Dr. Pejcic Ana

Assistant Medical Faculty Department of Periodontology and Oral Medicine University of Nis, Serbia

#### Dr. Ivandro Soares Monteiro

M.Sc., Ph.D. in Psychology Clinic, Professor University of Minho, Portugal

### Dr. Sanjay Dixit, M.D.

Director, EP Laboratories, Philadelphia VA Medical Center Cardiovascular Medicine - Cardiac Arrhythmia Univ of Penn School of Medicine Web: pennmedicine.org/wagform/MainPage.aspx?

### Antonio Simone Laganà

M.D. Unit of Gynecology and Obstetrics

Department of Human Pathology in Adulthood and
Childhood "G. Barresi" University of Messina, Italy

#### Dr. Han-Xiang Deng

MD., Ph.D

Associate Professor and Research Department

Division of Neuromuscular Medicine

Davee Department of Neurology and Clinical

Neurosciences

Northwestern University Feinberg School of Medicine

Web: neurology.northwestern.edu/faculty/deng.html

#### Dr. Roberto Sanchez

Associate Professor

Department of Structural and Chemical Biology

Mount Sinai School of Medicine

Ph.D., The Rockefeller University

Web: mountsinai.org/

### Dr. Feng Feng

Boston University

Microbiology

72 East Concord Street R702

Duke University

United States of America

#### Dr. Hrushikesh Aphale

MDS- Orthodontics and Dentofacial Orthopedics.

Fellow- World Federation of Orthodontist, USA.

#### Gaurav Singhal

Master of Tropical Veterinary Sciences, currently pursuing Ph.D in Medicine

#### Dr. Pina C. Sanelli

Associate Professor of Radiology

Associate Professor of Public Health

Weill Cornell Medical College

Associate Attending Radiologist

NewYork-Presbyterian Hospital

MRI, MRA, CT, and CTA

Neuroradiology and Diagnostic Radiology

M.D., State University of New York at Buffalo,

School of Medicine and Biomedical Sciences

Web: weillcornell.org/pinasanelli/

#### Dr. Michael R. Rudnick

M.D., FACP

Associate Professor of Medicine

Chief, Renal Electrolyte and Hypertension Division (PMC)

Penn Medicine, University of Pennsylvania

Presbyterian Medical Center, Philadelphia

Nephrology and Internal Medicine

Certified by the American Board of Internal Medicine

Web: uphs.upenn.edu/

#### Dr. Seung-Yup Ku

M.D., Ph.D., Seoul National University Medical College, Seoul, Korea Department of Obstetrics and Gynecology

Seoul National University Hospital, Seoul, Korea

#### Santhosh Kumar

Reader, Department of Periodontology,

Manipal University, Manipal

#### Dr. Aarti Garg

Bachelor of Dental Surgery (B.D.S.) M.D.S. in Pedodontics and Preventive Dentistr Pursuing Phd in Dentistry

### Sabreena Safuan

Ph.D (Pathology) MSc (Molecular Pathology and Toxicology) BSc (Biomedicine)

#### Getahun Asebe

Veterinary medicine, Infectious diseases, Veterinary Public health, Animal Science

#### Dr. Suraj Agarwal

Bachelor of dental Surgery Master of dental Surgery in Oromaxillofacial Radiology.

Diploma in Forensic Science & Oodntology

#### Osama Alali

PhD in Orthodontics, Department of Orthodontics, School of Dentistry, University of Damascus. Damascus, Syria. 2013 Masters Degree in Orthodontics.

#### Prabudh Goel

MCh (Pediatric Surgery, Gold Medalist), FISPU, FICS-IS

#### Raouf Hajji

MD, Specialty Assistant Professor in Internal Medicine

#### Surekha Damineni

Ph.D with Post Doctoral in Cancer Genetics

#### Arundhati Biswas

MBBS, MS (General Surgery), FCPS, MCh, DNB (Neurosurgery)

#### Rui Pedro Pereira de Almeida

Ph.D Student in Health Sciences program, MSc in Quality Management in Healthcare Facilities

#### Dr. Sunanda Sharma

B.V.Sc.& AH, M.V.Sc (Animal Reproduction,
Obstetrics & gynaecology),
Ph.D.(Animal Reproduction, Obstetrics & gynaecology)

#### Shahanawaz SD

Master of Physiotherapy in Neurology PhD- Pursuing in Neuro Physiotherapy Master of Physiotherapy in Hospital Management

#### Dr. Shabana Naz Shah

PhD. in Pharmaceutical Chemistry

#### Vaishnavi V.K Vedam

Master of dental surgery oral pathology

#### Tariq Aziz

PhD Biotechnology in Progress

## CONTENTS OF THE ISSUE

- i. Copyright Notice
- ii. Editorial Board Members
- iii. Chief Author and Dean
- iv. Contents of the Issue
- 1. High Voltage Mercury Amalgam Dental Fillings, Medical Considerations. 1-4
- 2. Gender Determination by Measuring the Mandibular Ramus and Body of the Mandible: A Retrospective Radiographic Study. *5-14*
- 3. Oral Complications in Cancer Patients: The Role of Chemotherapy and Radiotherapy. 15-23
- v. Fellows
- vi. Auxiliary Memberships
- vii. Preferred Author Guidelines
- viii. Index



### GLOBAL JOURNAL OF MEDICAL RESEARCH: J DENTISTRY & OTOLARYNGOLOGY

Volume 24 Issue 1 Version 1.0 Year 2024

Type: Double Blind Peer Reviewed International Research Journal

Publisher: Global Journals

Online ISSN: 2249-4618 & Print ISSN: 0975-5888

# High Voltage Mercury Amalgam Dental Fillings, Medical Considerations

By Stephen Bourne MB, MRCGP

Abstract- Dental amalgam contains 50% mercury, copper, silver and tin. These metals bathed in acid saliva form a battery. Experience collaborating with a mercury-free dentist indicates that the metallic dental fillings most urgently needing replacement are those with the highest associated voltages (>100mVs).

Electrical currents caused by mercury amalgam dental fillings are liable to be associated with chronic illness, and replacing them with non-metallic, non-toxic dental material can be therapeutic.

An earthing mat (9) that removes static electricity from patients with high-voltage mercury amalgam dental fillings can cause symptomatic relief.

Two clinical cases are presented as evidence of the concept.

GJMR-J Classification: FOR Code: 1105



Strictly as per the compliance and regulations of:



© 2024. Stephen Bourne MB, MRCGP. This research/review article is distributed under the terms of the Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0). You must give appropriate credit to authors and reference this article if parts of the article are reproduced in any manner. Applicable licensing terms are at https://creativecommons.org/licenses/by-nc-nd/4.0/.

# High Voltage Mercury Amalgam Dental Fillings, Medical Considerations

Stephen Bourne MB, MRCGP

Abstract- Dental amalgam contains 50% mercury, copper, silver and tin. These metals bathed in acid saliva form a battery. Experience collaborating with a mercury-free dentist indicates that the metallic dental fillings most urgently needing replacement are those with the highest associated voltages (>100mVs).

Electrical currents caused by mercury amalgam dental fillings are liable to be associated with chronic illness, and replacing them with non-metallic, non-toxic dental material can be therapeutic.

An earthing mat (9) that removes static electricity from patients with high-voltage mercury amalgam dental fillings can cause symptomatic relief.

Two clinical cases are presented as evidence of the concept.

#### I. Introduction

he toxic properties of dental mercury are well-known(1, 2, 3), and dental mercury is banned in the Scandinavian countries (4). There are no published UK studies in this field.

Dental assistants must wear protective clothing when handling dental amalgam. After dentists have removed mercury amalgam dental fillings from their patients' mouths, they must dispose of them in sealed containers so that mercury vapour from the amalgam dental fillings cannot contaminate the ecosystem. The British Dental Association (BDA) has not explained why it considers dental mercury amalgam toxic when handled by dental technicians and when disposed of, but not harmful inside people's mouths.

The BDA advises that although dental mercury is toxic for pregnant women and children, it is not for adults. It has yet to explain how it has reached this conclusion.

The BDA's recommendation does not take into account environmental research (2,4), clinical research (1,4,5,6) and animal research (12),all of which indicate that dental mercury is toxic.

The BDA should consider dental research, which has become possible with the Jerome J431-X and the new J4045.0 mercury vapour analysers. This technology measures levels of oral mercury and has shown that heavy chewing (e.g. chewing gum) and drinking hot drinks cause significant release of mercury vapour from amalgam dental fillings into subjects' mouths. Dr Hesham El-Essawy, a London Harley Street

dentist, has demonstrated this technology to the author. Such release of mercury vapour from amalgam dental fillings into subjects' mouths is inconsistent with the BDA's assertion that amalgam dental fillings are stable and not a source of mercury poisoning.

A meta-analysis of patients treated for dental mercury toxicity has shown that 89% of 1569 patients treated experienced 'that their symptoms had improved or were eliminated after the safe replacement of their mercury amalgam dental fillings (5).'

Mercury from dental amalgam fillings is a systemic toxin that can contribute to the pathogenesis of many chronic medical conditions, particularly anxiety, phobias, Parkinson's syndrome, multiple sclerosis, allergies, chronic fatigue syndrome, irritable bowel syndrome, arthritis and stroke (6).

#### I. Case Reports

a) Case 1

During 1981, a fifty-one-year-old patient with malignant hypertension and severe chronic migraine joined my NHS general practice. His symptoms had not responded to conventional medical treatment for hypertension from his previous GP, from me and subsequently from several private consultant physicians. He was eventually treated successfully by George Le with MRCP (deceased), who identified high-voltage mercury amalgam dental fillings as the cause of his migraine and hypertension. Dr Le with referred my patient to a mercury-free dentist who was a member of the British Society for Mercury-free Dentistry (7).

For replacement of his pathogenic high-voltage mercury amalgam dental fillings. The patient's migraine and hypertension cleared up immediately after the dentist had replaced his high-voltage metallic mercury amalgam dental fillings.

At the time, the patient was incapacitated by chronic poor health. Since replacing his high-voltage amalgam dental fillings, he led a full and active life.

Here is the patient's account.

"In 1981, I was aged fifty-one and seriously ill with malignant hypertension and migraine. Conventional medical treatment had not helped. My GP, Dr Bourne, eventually suggested that I consult Dr George Le with at his clinic on Upper Harley Street. Dr Le with compared my amalgam dental fillings to 'having a battery in my

Author: e-mail: valstevb@hotmail.com

mouth'. He used a simple DC voltmeter to measure the voltages at my amalgam dental fillings.

As an electrical engineer, I did not find it surprising that Dr Le with identified my high-voltage amalgam dental fillings (> 1.5 Volts) as the causes of my migraine and high blood pressure.

The rest is history. Dr Le with referred me to a mercury-free dentist, who replaced my high-voltage amalgam dental fillings. The result was quick and astonishing: the migraines and malignant hypertension ceased straightaway, and there was also an improvement in my energy levels. Removing my high voltage amalgam dental fillings has been a lifeenhancing procedure."

Here is the account of another patient with highvoltage amalgam dental fillings.

#### b) Case 2

"I first consulted Dr Bourne in August 2020 because I had been feeling abnormally tired for years. He identified two high-voltage mercury amalgam dental fillings as the cause of my tiredness. He advised me to consult a mercury-free dentist to have my 'silver' mercury amalgam dental fillings replaced.

I visited a mercury-free dentist in September; the fillings were replaced in November.

Since they were replaced, I have no longer felt abnormally tired and have been able to concentrate better at work. My tiredness cleared up immediately the silver fillings were changed. Dr Bourne explained that this was due to removing the mercury amalgamassociated electric currents in my mouth.

I used to have a sore throat every winter, which returned in September this year. My sore throat cleared immediately after my high voltage dental fillings were replaced."

#### III. DISCUSSION

The two case histories correlate with an association between high-voltage mercury amalgam dental fillings and chronic poor health. Further clinical experience will indicate whether this association can be replicated in a cohort of suitable subjects.

While in NHS general practice, I noticed that some patients with chronic fatigue syndrome (CFS) who had not responded to conventional medical treatment had high-voltage' silver' dental amalgam fillings. Although one such patient made a remarkable recovery from CFS after a private dentist replaced his highvoltage mercury fillings, most NHS patients could not afford such private dental treatment, and my attempts to have their high-voltage fillings replaced within the NHS were unsuccessful.

During retirement from general practice, while specialising in integrative medicine, I found that several chronically ill patients who had not responded to conventional medical treatment had high-voltage metallic mercury amalgam dental fillings. symptoms improved immediately after their high-voltage mercury amalgam fillings were replaced.

Autopsy research on cadavers has shown that mercury from dental amalgam is deposited in body organs proportionately to the number of amalgam dental fillings and to the number of years that they have been in place (10). At autopsy, the highest mercury concentrations were found in the brain, thyroid gland and kidneys. Given this finding, it is improbable that replacing patients' mercury amalgam dental fillings would cause a sufficient reduction in systemic mercury poisoning to account for the immediate clinical improvements reported in the above two case histories. The immediate clinical improvements were associated with an immediate cessation of dental amalgamgenerated electric currents.

Dental mercury molecules are liable to be deposited in the brain (10), becoming micro aerials that attract harmful electromagnetic radiation so that people with mercury amalgam dental fillings can feel abnormally tired when visiting electrically charged places such as airports and underground railways (11).

Mercury deposited in sheep kidneys has been shown to significantly impair their renal function (12). This finding is consistent with a higher incidence of dialysis-dependent renal failure patients in countries whose residents can afford only mercury amalgam dental fillings rather than more expensive, less toxic alternatives. (13).

Given these considerations, further clinical research is indicated to investigate the anticipated correlation between high-voltage mercury amalgam dental fillings and health deterioration. Such research would entail doctors routinely using voltmeters to measure the voltages associated with metallic dental fillings in chronically ill patients' mouths. When dental fillings with voltages above 100 mV are found in patients' mouths (14,15), they should be referred to dentists with post-graduate expertise in mercury-free dentistry (7) to have their pathogenic high-voltage mercury amalgam dental fillings safely replaced.

#### IV. Conclusion

Mercury amalgam dental fillings can cause pathogenic oral electric currents. They can also cause pathogenic mercury deposits in the body's vital organs and health deterioration (1, 2, 3, 4, 5, 6, 10, 11, 12, 13). Given these considerations, the use of mercury amalgam in dentistry should be discontinued.

#### References Références Referencias

1. A snapshot of dentistry in Europe AIOB. Raymondo Pische MD, DDS. (replace mercurymercury2017. Rio.pdf). Mercury, in all forms, poisons cellular function by altering proteins' tertiary and quaternary structure and binding with sulfhydryl Suppose the BDA accepts that high-voltage mercury-containing dental fillings are pathogenic in that case. Mercury toxicity can also impair the function of any organ or subcellular structure. The chief target area of mercury is the brain, but peripheral nerve function, renal function, endocrine and muscle function, and several types of dermatitis have been described. Dental mercury interferes with DNA transcription and protein synthesis in the developing brain, destroying the endoplasmic reticulum and causingthe disappearance of ribosomes. Mercury poisoning also causes kidney toxicity, autoimmune conditions, immune system dysfunction and hypersensitivity reactions such as asthmaand dermatitis.

- The environmental impact of dental amalgam and resin-based composite materials. S. Mulligan,1, G. Kakonyi,2 K. Moharamzadeh,1 S. F. Thornton2 and N. Martin BRITISH DENTAL JOURNAL | VOLUME 224 NO. 7 | APRIL 13, 201
- "Never has so much harm been done to so many by so few."
  - Professor Murray J Vimy, Professor of Oral Medicine at Calgary University, Canada, spoke about dental mercury in 2000.
- Mercury in dental-filling materials updated risk analysis in environmental and medical terms. An overview of scientific literature published in 1997– 2002 and current knowledge.
  - In 1998, a report commissioned by the Swedish Government stated that 'mercury from amalgam fillings is liable to damage the central nervous system, the kidneys and the immune system'. The Swedish Dental Material Commission advised that exposure to dental mercury amalgams is hazardous and can be deposited in the thyroid gland, the retina of the eye, and the testicles.
  - Seychelles Medical and Dental Journal, Special Issue, Vol 7, No 1, November 2004 Maths Berlin MD, PhD. Emeritus Environmental Health, University of Lund, Sweden.
- 5. DENTISTRY WITHOUT MERCURY by Sam Ziff and Michael Ziff. 2001.ISBN 0-941011-04-6.
- 6. TOXIC DENTISTRY EXPOSED (the link between dentistry and chronic disease). Graham Munro Hall BDS and Lilian Munro Hall BDS.
- 7. British Society for Mercury Free Dentistry (http://mercuryfreedentistry.org.uk).
- 8. Judith Moore et al. Why do people seek alternative therapies? British Medical Journal (1985),
  - 290, 29-29. In 1985, a group of British doctors (Julian Kenyon, David Dowson and George Le with), who practised vegatesting in Southampton at the Centre for The Study of Complementary Medicine authorised a survey of their practice success rate to be carried out by senior medical students, and the findings were in a letter to the British Medical

Journal. In the letter, it was pointed out that only about 20% of techniques employed by conventional doctors have been properly evaluated. The survey found that most clinic patients had long-term health problems, and 60-70% experienced significant health improvements after attending the clinic for only eight weeks. Such improvements were impressive the patients as had been treatedunsuccessfully with conventional medicine for up to ten years.

- 9. Earthing mats are available from Groundology.
- Dental Amalgam and Mercury Levels in Autopsy Tissues: Food for Thought. Guzzi, Gianpaolo DDS\*; Grandi, Marco MD†; Cattaneo, Cristina PhD†; Calza, Stefano MSc<sup>\$</sup>; Minoia, Claudio BSc<sup>‡</sup>; Ronchi, Anna BSc<sup>‡</sup>; Gatti Anna BSc<sup>‡</sup>; Severi, Gianluca PhDI<sup>II</sup>. The American Journal of Forensic Medicine and Pathology: March 2006 -Volume 27 Issue 1 p 42-45

#### **Abstract**

Eighteen cadavers from routine autopsy casework were subject to a study of tissue levels of total mercury in the brain, thyroid, and kidney samples by atomic absorption. On these same cadavers, all dental amalgam fillings, the most essential source of organic mercury exposure in the general population, according to the World Health Organization (WHO), were charted. Total mercury levels were significantly higher in subjects with a more significant number of occlusal amalgam surfaces (>12) compared with those with fewer occlusal amalgams (0-3) in all types of tissue (all P ≤ 0.04). Mercury levels were significantly higher in brain tissues compared with thyroid and kidney tissues in subjects with more than 12 occlusal amalgam fillings (all  $P \le 0.01$ ) but not in subjects with three or fewer occlusal amalgams (all P ≥ 0.07).

- 11. Dirty Electricity. Samuel Milham MD, MPH. iUniverse.com. 2010.ISBN: 13:978-1450238229.
- Mercury from dental "silver" tooth fillings impairs sheep kidney function. Boyd N.D; Benediktsson, H; Vimy MJ; D.E. Hooper, and Lorscheider F.; Am. J. Physiol. 261, (Regulatory Integrative Comp. Physiol. 30): R1010- R1014, 199

#### **Abstract**

Within thirty days after placing twelve occlusal amalgam fillings in six adult sheep, there was a 50% kidney function impairment. After sixty days, there was 60%. impairment in renal function.

13. During a lecture at the Royal London Hospital about twenty-five years ago, Prof Blandy (professor of nephrology) pointed out that renal failure is statistically much higher in wealthy than poor, undeveloped countries. He subsequently agreed with me that this is likely to be due to the extensive

- use of dental mercury in wealthy countries, and he agreed with my suggestion of research to measure the voltages associated with the amalgam fillings of teeth in renal failure patients and to compare them with those of age-matched controls. This suggested research was not allowed because it was unfunded.
- 14. Set an electrician's voltmeter to measure up to 2 volts (2000 millivolts). Place one probe gently on the inside of the patient's cheek (buccal mucosa) and the other gently on the 'silver' dental filling being investigated. Record the positions and voltages of all the teeth with voltages above 100 millivolts because the amalgam fillings in these teeth will be replaced first. Ideally, all the mercury amalgam dental fillings should eventually be replaced.
- 15. This recommendation is based on over forty years of clinical experience.



# GLOBAL JOURNAL OF MEDICAL RESEARCH: J DENTISTRY & OTOLARYNGOLOGY

Volume 24 Issue 1 Version 1.0 Year 2024

Type: Double Blind Peer Reviewed International Research Journal

Publisher: Global Journals

Online ISSN: 2249-4618 & Print ISSN: 0975-5888

# Gender Determination by Measuring the Mandibular Ramus and Body of the Mandible: A Retrospective Radiographic Study

By Dr. Kirti Saharan, Dr. Shivaprasad S. & Dr. Ashok L.

Abstract- Aims: 1) To measure the height and width of the mandibular ramus and height of the body of the mandible on digital orthopantomograms. 2) To compare the measurements on the mandibular ramus & body of the mandible and use them in gender determination.

Setting and Design: Retrospective study on 120 retrieved digital orthopantomograms of individuals of Indian origin.

Materials and Methods: A study was conducted on 120 retrieved digital orthopantomograms which were categorized into three age groups of age between 21-50 years. 40 digital orthopantomograms were selected under each age group which included 20 male and 20 female radiographs. The Digital OPG images that were obtained using the PLANMECA PROLINE XC machine were measured using PLANMECA ROMEXIS 2.3.1.R software.

Keywords: forensic odontology, gender determination, identification, mandibular ramus, digital orthopantomograms, height of the body of mandible.

GJMR-J Classification: NLMC Code: WW270-290



Strictly as per the compliance and regulations of:



© 2024. Dr. Kirti Saharan, Dr. Shivaprasad S. & Dr. Ashok L. This research/review article is distributed under the terms of the Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0). You must give appropriate credit to authors and reference this article if parts of the article are reproduced in any manner. Applicable licensing terms are at https://creativecommons.org/licenses/by-nc-nd/4.0/.

# Gender Determination by Measuring the Mandibular Ramus and Body of the Mandible: A Retrospective Radiographic Study

Dr. Kirti Saharan a, Dr. Shivaprasad S. & Dr. Ashok L.

Abstract- Aims: 1) To measure the height and width of the mandibular ramus and height of the body of the mandible on digital orthopantomograms. 2) To compare the measurements on the mandibular ramus & body of the mandible and use them in gender determination.

Setting and Design: Retrospective study on 120 retrieved digital orthopantomograms of individuals of Indian origin.

Materials and Methods: A study was conducted on 120 retrieved digital orthopantomograms which were categorized into three age groups of age between 21-50 years. 40 digital orthopantomograms were selected under each age group which included 20 male and 20 female radiographs. The Digital OPG images that were obtained using the PLANMECA PROLINE XC machine were measured using PLANMECA ROMEXIS 2.3.1.R software.

Statistical analysis used: The measurements of the mandibular ramus and body were subjected to ROC curve analysis and Bland Altman analysis.

Results: The best parameter in determining gender were the Condylar Height followed by the Coronoid Height and the Projective Height of Ramus. The overall prediction accuracy for mandibular ramus parameters came out to be 80.5% and for the body of the mandible parameter it came out to be 76.7%.

Conclusion: Mandibular ramus has a better potential than the body of the mandible in terms of gender determination.

Keywords: forensic odontology, gender determination, identification. mandibular ramus. digital orthopantomograms, height of the body of mandible.

#### Introduction I.

keleton has always helped genetic, anthropological, odontological forensic investigation of living and dead individuals. Skull bones and pelvis are the most commonly used bones in gender and age determination.1 The mandible is the most dimorphic and strongest bone of the skull and therefore, it is useful for gender and race determination

Author α: Specialist Dentist, 156-08, Riverside Drive West, Apt 1j, Manhattan, New York. e-mail: kirtisaharan91@gmail.com

Author o: Professor, Dept of Oral Medicine and Radiology Bapuji Dental College and Hospital Davangere, Karnataka.

e-mail: gauravgautham@gmail.com

Author p: Professor and HOD Dept of Oral Medicine and Radiology Bapuji Dental College and Hospital Davangere, Karnataka.

e-mail: ashoklingappa1@gmail.com

in forensic and archaeological cases where intact skull is not found.<sup>2</sup> Sexual dimorphism in the mandible is noticed in its shape and size. Previous studies have shown that the difference between sexes are generally more significant in the mandibular ramus than the body because the relative development (size, strength, and angulation) of the muscles of mastication affects the gender expression of mandible as the masticatory forces exerted are different for men and women<sup>3</sup>

Panoramic radiography has been used as an important tool in forensic anthropology and studies have been conducted to make a biometric system for human identification. It is commonly used for obtaining a comprehensive overview of the maxillofacial complex and the image quality of the panoramic radiograph is increased by the digital panoramic radiography. The advantages of digital images are their broad anatomical coverage, low patient exposure, and less time required for image acquisition and the disadvantages are magnification, geometric distortion and positioning errors.4,5

Normally morphological and metric methods are used to estimate the gender of a mandible. The mandibles of males and females are differentiated by their size, chin shape, muscular markings, and gonial angle or flare. Determining sex using metric parameters like condylar breadth, coronoid breadth, gonial breadth, ramus breadth and height, height of the body of mandible, etc. are easy and more reliable compare to methods.6 traditional non-metric Therefore, combining the reliable metric parameters and digital radiography we can get a more accurate gender estimation.

#### AIMS & OBJECTIVES П.

- To compare the measurements on the mandibular ramus & body of the mandible and use them in gender determination among various age groups.
- To measure the width & height of mandibular ramus and height of the body of mandible on digital orthopantomograms among various age groups.

#### Materials and Methods III.

A retrospective study was conducted on 120 digital orthopantomograms of the Indian individuals, which were later divided into three age groups of age between 21-30 years, 31-40 years and 41-50 years respectively. 40 digital orthopantomograms were taken under each age group consisting of 20 males and 20 females. Ideal Orthopantomograms of the patients with full set of permanent teeth, minimal alveolar bone loss and without any artefacts were included in the study whereas radiographs with developmental disturbances of the skull, mandibular deformities, pathologies, fractures and distorted digital images were excluded from the study.

The Digital OPG images that was obtained using PLANMECA PROLINE XC machine were measured using PLANMECA ROMEXIS 2.3.1.R software. The following measurements were taken on the right side of OPG's digitally (Fig.1 & Fig.2):

- 1. Maximum ramus breadth: The distance between the most anterior point on the mandibular ramus and a line connecting the most posterior point on the condyle and the angle of jaw.
- 2. Minimum ramus breadth: Smallest anterior-posterior diameter of the ramus.
- Condylar height/maximum ramus height: Height of the ramus of the mandible from the most superior point on the mandibular condyle to the tubercle, or most protruding portion of the inferior border of the
- 4. Projective height of ramus: Projective height of ramus between the highest point of the mandibular condyle and lower margin of the bone.

- 5. Coronoid height: Projective distance coronion and lower wall of the bone.7
- Height of the body of mandible: The distance from the inferior surface of the mandibular body to the height of the alveolar crest.

To eliminate the inter-observer variations and determination of reliability and reproducibility of the measurements, the images were evaluated by two qualified Oral Radiologist under standard conditions in a semi-dark room with ambient light & using magnifying lens icon.

#### STATISTICAL ANALYSIS IV.

Mean comparison between the age groups were done using Independent Student t-test. ANOVA test was used to compare the difference in the means of three groups for individual parameter for both the observers. ROC (Receiver operating characteristic) curve analysis was used to estimate the cut-off value for males and females, sensitivity and specificity for individual parameters among various age groups. This analysis has not been done in the literature before for similar kind of studies. Bland Altman analysis was used estimating agreement between observer 1 observer 2.

#### V. RESULTS

Statistical analysis showed that each variable was a significant predictor in classifying a given sample (P < 0.001). The mean values for all the measurements were higher for the males as compared to the females. (Table 1)

Table 1: Total Mean and Standard Deviation for All the Parameters among Males and Females (Observer 1 & 2)

|                     |     |                |              | Ob 1                |         |              | Ob 2                      |         |
|---------------------|-----|----------------|--------------|---------------------|---------|--------------|---------------------------|---------|
| Parameters          | Sex | Sample<br>Size | Mean<br>(mm) | Std. Deviation (mm) | P-Value | Mean<br>(mm) | Std.<br>Deviation<br>(mm) | P-Value |
| Maximum             | М   | 60             | 37.2         | 2.79                | 0.027   | 37.9         | 2.68                      | 0.131   |
| Ramus Breadth       | F   | 60             | 34.3         | 2.80                | 0.075   | 34.6         | 2.86                      | 0.310   |
| Minimum Ramus       | М   | 60             | 29.0         | 2.14                | 0.810   | 28.0         | 2.12                      | 0.883   |
| Breadth             | F   | 60             | 27.3         | 2.58                | 0.342   | 26.3         | 2.48                      | 0.383   |
| Condylar Height     | М   | 60             | 62.9         | 4.11                | 0.293   | 62.8         | 4.10                      | 0.343   |
| Oorlaylar Holgin    | F   | 60             | 55.9         | 3.14                | 0.109   | 56.0         | 3.02                      | 0.165   |
| Projective Height   | М   | 60             | 60.7         | 4.17                | 0.171   | 60.8         | 4.10                      | 0.310   |
| of Ramus            | F   | 60             | 54.0         | 3.55                | 0.168   | 53.9         | 3.47                      | 0.321   |
| Coronoid Height     | М   | 60             | 56.7         | 4.45                | 0.963   | 56.2         | 4.35                      | 0.911   |
| Coronola Height     | F   | 60             | 50.2         | 2.88                | 0.756   | 49.8         | 2.87                      | 0.546   |
| Height of the       | М   | 60             | 28.9         | 2.40                | 0.635   | 28.8         | 2.50                      | 0.776   |
| Body of<br>Mandible | F   | 60             | 26.0         | 2.09                | 0.821   | 25.9         | 2.18                      | 0.884   |

The Bland & Altman analysis for inter-observer agreement showed statistically significant evidence of agreement between both the observers.

According ROC analysis to curve the decreasing order of various parameters for sensitivity for cut-off values in males and females was:

Projective Height of Ramus > Condylar Height > Minimum Ramus Breadth = Coronoid Height > Maximum Ramus Breadth > Height of the Body of Mandible.

The decreasing order of various parameters for the specificity for cut-off values in males and females was: Height of the Body of Mandible > Coronoid Height > Condylar Height > Projective Height of Ramus > Maximum Ramus Breadth > Minimum Ramus Breadth.

The decreasing order of various parameters on mandibular ramus and body according to prediction accuracy was: Condylar Height > Coronoid Height = Projective Height of Ramus > Height of the Body of Mandible > Maximum Ramus Breadth > Minimum Ramus Breadth.

The overall prediction accuracy for mandibular ramus parameters came out to be 80.5% whereas the overall prediction accuracy for mandibular body parameter came out to be 76.7%.

#### VI. Discussion

In the present study a total of six parameters were measured namely; maximum ramus breadth, minimum ramus breadth, condylar height, projective height of ramus, coronoid height and height of the body of mandible which were similar to the study carried out by Saini V et al.7 (2011), Indira AP et al.4 (2012), Samantha K et al.8 (2016), Sairam V et al.9 (2016), Jambunath U et al. 10 (2016), Kartheeki B et al. 11 (2017).

#### 1. Maximum ramus breadth

In the present study, the average cut-off point for Maximum Ramus Breadth in males and females of all the groups came out to be 34.9mm which was similar to that in the study conducted by Sikka A et al. 12 (2016) in which it was 35mm and lesser than the cut-off point taken in the study conducted by Vinay G et al. 13 (2013) in which it was 39.5mm.

In the present study, the accuracy of Maximum Ramus Breadth for males was 83.3% and for females was 66.7% which was greater than in the study conducted by Vinay G et al. 13 (2013) in which it was 72.08% for males and 63.64% for females. It was also greater than the male accuracy and lesser that the female accuracy in the study conducted by Dong H et al.6 (2015) in which it was 69.8% and 76.6%. The combined accuracy for Maximum Ramus Breath was 75% which was greater than in the study done by Saini V <sup>14</sup> (2013) in which it was 65.3% and *Dong H* et al.<sup>6</sup> (2015) in which it was 73.4%.

#### 2. Minimum ramus breadth

In the present study, the average cut-off point for Minimum Ramus Breadth in males and females of all the groups came out to be 27.1mm which was lesser than the cut-off point taken in the study conducted by Saini V et al.7 (2011) and Vinay G et al.13 (2013) in which it was 30.5mm.

In the present study, the accuracy of Minimum Ramus Breadth for males was 85% and for females was 55% which was greater than the male accuracy and lesser than the female accuracy noted in the study conducted by Vinay G et al.13 (2013) in which it was 68.18% for males and 62.12% for females. The combined accuracy for Minimum Ramus Breath was 70% which was greater than in the study done by Saini V <sup>14</sup> (2013) in which it was 63.2%.

#### 3. Condylar height

In the present study, the average cut-off point for Condylar Height in males and females of all the groups came out to be 57.7mm which was lesser than the cut-off point taken in the study conducted by Datta A et al.15 (2015) in which it was 61.5mm and greater than the cut-off point taken in the study conducted by Franklin D et al. 16 (2008) in which it was 53.8mm. But it was similar to the cut-off value given by Saini V et al.7 (2011) in which it was 57.6mm.

In the present study, the accuracy of Condylar Height for males was 93.3% and for females was 81.7% which was nearly similar to the accuracy noted in the study conducted by Datta A et al.15 (2015) in which it was 96% for males and 84% for females. But our accuracy was greater than the accuracy noted in the study conducted by Saini Vet al.7 (2011) in which it was 73.9% of males and 66.7% for females, Dong H et al.6 (2015) in which it was 72.9% for males and 80.4% for females. The combined accuracy for Condylar Height was 87.5% which was greater than in the study done by Franklin D et al. 16 (2008) in which it was 73.8%. Saini V et al.7 (2011) in which it was 72.4% and Dong H et al.6 (2015) in which it was 76.8%.

#### 4. Projective height of ramus

In the present study, the average cut-off point for Projective Height of Ramus in males and females of all the groups came out to be 55.6mm which was greater than the cut-off point taken in the study conducted by Saini V et al.7 (2011) in which it was 50.7mmand also greater than the cut-off point taken in the study conducted by Datta A et al. 15 (2015) in which it was 50.1mm.

In the present study, the accuracy of Projective Height of Ramus for males was 95% and for females was 75% which was greater than the accuracy noted in the study conducted by Saini V et al.7 (2011) in which it was 65.2% for males & 79.2% for females and also greater than the male accuracy in the study conducted by Wankhede KP et al. 17 (2015) in which it was 76.4% but lesser than the female accuracy which was 81.5%. The combined accuracy for Projective Height of Ramus was 85% which was greater than in the study done by Saini V at al.7 (2011) in which it was 68.1% and Wankhede KP et al.<sup>17</sup> (2015) in which it was 78%.

#### 5. Coronoid height

In the present study, the average cut-off point for Coronoid Height in males and females of all the groups came out to be 52.8mm which was lesser than the cut-off point taken in the study conducted by Saini V et al.17 (2011) in which it was 58.3mmand also lesser than the cut-off point taken in the study conducted by Datta A et al.25 (2015) in which it was 56.7mm. But our value is somewhat near to the value given in the study conducted by Franklin D et al. 16 (2008) in which it was 55.5mm

In the present study, the accuracy of Coronoid Height for males was 83.3% and for females was 86.7% which was greater than the accuracy noted in the study conducted by Saini Vet al.7 (2011) in which it was 73.9% for males & 75% for females. But it was lesser than the male accuracy and greater than the female accuracy in the study conducted by Datta A et al. 15 (2015) in which it was 84% for both males and females. The combined accuracy for Coronoid Height was 85% which was greater than in the study done by Franklin D et al. <sup>16</sup>(2008) in which it was 73.3% and Saini V et al. (2011) in which it was 74.1%.

#### Height of the body of mandible

In the present study, the average cut-off point for the Height of the Body of Mandible in males and females of all the groups came out to be 28.3mm which was greater than the cut-off point taken in the study conducted by Sikka A et al.12 (2016) in which it was 23.0mm and almost close to the cut-off point taken in the study conducted by Datta A et al. 15 (2015) and Wankhede KP et al. 17 (2015) in which it was 25.7mm.

In the present study, the accuracy of the Height of the Body of Mandible for males was 63.3% and for females was 90%. It was lesser than the male accuracy and greater than the female accuracy noted in the study conducted by Wankhede KP et al. 17 (2015) & Datta A et al. 15 (2015) in which it was 70.9% & 88% for males & 51.9% & 76% for females. The combined accuracy for the Height of the Body of Mandible was 76.7% which was greater than in the study done by Saini V 14 (2013). Wankhede KP et al. 17 (2015) and Sikka A et al. 12 (2016) in which it was 67.4%, 64.6% and 69.2%.

In the present study, the highest sexual dimorphism was seen with Condylar Height followed by Projective Height of Ramus and Coronoid Height which was similar to the study conducted by Indira AP et al.4 (2012) & Kartheeki B et al. 11 (2017) in which all variables showed strong sexual dimorphism with the mandibular ramus in terms of condylar height, coronoid height followed by projective height of ramus. In the present study least sexual dimorphism was noticed with the Minimum Ramus Breadth similar to the study conducted by Saini V et al.7 (2011) and Samantha K et al.8 (2016).

In the present study, the overall prediction accuracy for Mandibular Ramus parameters in males was 88% and in females was 73% with a combined accuracy of 80.5% which was almost similar to the study conducted by Saini V et al.7 (2011) the overall prediction rate using five variables was 80.2% and also similar to the study conducted by Kartheeki B et al. 11 (2017) where overall prediction rate using all the five variables was 80.4%.

The overall prediction accuracy for the Height of the Body of Mandible in males was 63.3% and in females was 90% with a combined accuracy of 76.7%. This proved that the Mandibular Ramus parameters are more significant than the Height of the Body of Mandible measurement parameter in determining gender on the digital orthopantomograms.

Limitations of the present study are the inability to reliably estimate gender in the sub-adult range, edentulous patients, and severely deformed mandibular ramus.

#### VII. Conclusion

In conclusion, the ramus of the mandible has a better potential than the body of the mandible in determination of sex. However, larger sample size and more diverse population would enhance the reliability of this parameter.

#### References Références Referencias

- Rai B, Anand S, Madan M, Dhattarwal S. Criteria for Determination of Sex from Mandible. Internet J Dent Sci.2006; 4(2): 1-5.
- Muskaan A, Sarkar S. Mandible- An indicator for and sex determination using age Orthopantomogram. Sch J Dent Sci.2015; 2(1):
- Shivaprakash S, Vijaykumar AG. Sex Determination by Using Mandibular Ramus Posterior Flexure - A Prospective Study.Int J Health Sci Res. 2014; 4(1): 155-9.
- Indira AP, Markande A, David MP. Mandibular ramus: An indicator for sex determination- A digital radiographic study. J Forensic Sci. 2012 Jul-Dec; 4(2): 58-62.
- Xie Q, Wolf J, Ainamo A. Quantitative assessment of vertical heights of maxillary and mandibular bones in panoramic radiographs of elderly dentate and edentulous subjects. ActaOdontol Scand.1997; 55: 155-61.
- Dong H, Deng M, Wang WP, Zhang J, Mu J. Sexual dimorphism of the mandible in a contemporary Chinese Han population. J Forensic Sci Int.2015 Oct; 155: 9-15.
- Saini V, Srivastava R, Rai RK, Shamal SN, Singh TB, Tripathi SK. Mandibular ramus: An indicator for sex

- in fragmentary mandible. J Forensic Sci.2011; 56(Suppl1): S13-6.
- Samatha K, Byahatti SM, Ammanagi RA, Tantradi P, Sarang CK, Shivpuje P. Sex determination by mandibular ramus: A digital orthopantomographic study. J Forensic Dent Sci.2016; 8(2): 95-8.
- Sairam V, Geethamalika MV, Kumar PB, Naresh G, Raju GP. Determination of sexual dimorphism in humans by measurements of mandible on digital panoramic radiograph.Contemp Clin Dent.2016; 7(4): 434-9.
- 10. Jambunath U, Govindraju P, Balaji P, Poornima C, Latha S. Sex determination by using mandibular ramus and gonial angle - a preliminary comparative study. Int J Contemp Med Res. 2016; 3(11): 3278-80.
- 11. Kartheeki B, Nayyar AS, Sindhu UY. Accuracy of Mandibular Rami Measurements in Prediction of Sex.Ann Med Health Sci Res.2017; 7: 20-29.
- 12. Sikka A, Jain A. Sex determination of mandible: a morphological and morphometric analysis. Int J Contemp Med Res.2016; 3(7): 1869-72.

- 13. Vinay G, Mangala Gowri SR. Determination of Gender by the Anthropometric Measurement of Human Mandible Using Ramus Breadth and Mandibular Angle: A Cross Sectional Studyfrom South India. Med Sci.2013: 1(2): 28-32.
- 14. Saini V. Metric study of fragmentary mandibles in a North Indian population. Bull Int Assoc Paleodont.2013; 7(2): 157-62.
- 15. Datta A, Siddappa SC, Gowda VK, Channabasappa SR, Shivalingappa SBB, Srijith et al. A study of sex determination from human mandible using various morphometrical parameters. Ind J Forensic Community Med.2015 Jul-Sep; 2(3): 158-66.
- 16. Franklin D, O'Higgins P, Oxnard CE, Dadour T. Discriminant function sexing of the mandible of Indigenous South Africans. Forensic Sci Int.2008; 179: 84.e1-e5.
- 17. Wankhede KP, Bardale RV, Chaudhari GR, Kamdi NY. Determination of sex by discriminant function analysis of mandibles from a Central Indian population. J Forensic Dent Sci. 2015 Jan-Apr; 7(1): 37-43.

Table 2: Cut-Off Value for Males, Sensitivity and Specificity for Maximum Ramus Breadth in Various Age Groups (Observer 1 & 2)

| Age Groups           |                    | Ob 1        |             | Ob 2               |             |             |  |
|----------------------|--------------------|-------------|-------------|--------------------|-------------|-------------|--|
| (years)              | Cut off value (mm) | Sensitivity | Specificity | Cut off value (mm) | Sensitivity | Specificity |  |
| Group I<br>(21-30)   | > 34.5             | 70%         | 75%         | > 36.5             | 70%         | 90%         |  |
| Group II<br>(31-40)  | > 36.9             | 75%         | 85%         | > 37               | 90%         | 70%         |  |
| Group III<br>(41-50) | > 33.4             | 100%        | 40%         | > 36.9             | 55%         | 90%         |  |

Table 3: Cut-Off Value for Males, Sensitivity and Specificity for Minimum Ramus Breadth in Various Age Groups (Observer 1 & 2)

| Age Groups           |                    | Ob 1        |             | Ob 2               |             |             |  |
|----------------------|--------------------|-------------|-------------|--------------------|-------------|-------------|--|
| (years)              | Cut off value (mm) | Sensitivity | Specificity | Cut off value (mm) | Sensitivity | Specificity |  |
| Group I<br>(21-30)   | > 27.5             | 80%         | 75%         | > 26.2             | 85%         | 65%         |  |
| Group II<br>(31-40)  | > 26               | 100%        | 25%         | > 28.5             | 45%         | 90%         |  |
| Group III<br>(41-50) | > 27.9             | 70%         | 65%         | > 26.8             | 70%         | 65%         |  |

Table 4: Cut-Off Value for Males, Sensitivity and Specificity for Condylar Height on Right Side in Various Age Groups (Observer 1 & 2)

| Age Groups           |                       | Ob 1        |             | Ob 2                  |             |             |  |
|----------------------|-----------------------|-------------|-------------|-----------------------|-------------|-------------|--|
| (years)              | Cut off value<br>(mm) | Sensitivity | Specificity | Cut off value<br>(mm) | Sensitivity | Specificity |  |
| Group I<br>(21-30)   | > 56.4                | 95%         | 80%         | > 59.2                | 85%         | 95%         |  |
| Group II<br>(31-40)  | > 60.1                | 85%         | 90%         | > 60                  | 80%         | 95%         |  |
| Group III<br>(41-50) | > 56.6                | 100%        | 75%         | > 56.7                | 95%         | 80%         |  |

Table 5: Cut-Off Value for Males, Sensitivity and Specificity for Projective Height of Ramus on Right Side in Various Age Groups (Observer 1 & 2)

| Age Groups           |                       | Ob 1        |             | Ob 2                  |             |             |  |
|----------------------|-----------------------|-------------|-------------|-----------------------|-------------|-------------|--|
| (years)              | Cut off value<br>(mm) | Sensitivity | Specificity | Cut off value<br>(mm) | Sensitivity | Specificity |  |
| Group I<br>(21-30)   | > 55.6                | 95%         | 80%         | > 55.6                | 95%         | 80%         |  |
| Group II<br>(31-40)  | > 57.3                | 90%         | 80%         | > 58.8                | 75%         | 90%         |  |
| Group III<br>(41-50) | > 53.8                | 100%        | 65%         | > 53.7                | 100%        | 70%         |  |

Table 6: Cut-Off Value for Males, Sensitivity and Specificity for Coronoid Height on Right Side in Various Age Groups (Observer 1 & 2)

| Ago Groupo            |                    | Ob 1                    |      | Ob 2                  |               |     |  |
|-----------------------|--------------------|-------------------------|------|-----------------------|---------------|-----|--|
| Age Groups<br>(years) | Cut off value (mm) | Sensitivity Specificity |      | Cut off value<br>(mm) | i sensiliviiv |     |  |
| Group I<br>(21-30)    | > 51               | 100%                    | 75%  | > 51.5                | 100%          | 75% |  |
| Group II<br>(31-40)   | > 53               | 80%                     | 85%  | > 53                  | 85%           | 85% |  |
| Group III<br>(41-50)  | > 54.3             | 70%                     | 100% | > 52.5                | 80%           | 90% |  |

Table 7: Cut-Off Value for Males, Sensitivity and Specificity for Height of the Body of Mandible on Right Side in Various Age Groups (Observer 1 & 2)

| Age Groups           |                       | Ob 1        |             | Ob 2                  |             |     |  |
|----------------------|-----------------------|-------------|-------------|-----------------------|-------------|-----|--|
| (years)              | Cut off value<br>(mm) | Sensitivity | Specificity | Cut off value<br>(mm) | Sensitivity |     |  |
| Group I<br>(21-30)   | > 28.7                | 50%         | 100%        | > 25.8                | 90%         | 55% |  |
| Group II<br>(31-40)  | > 28.2                | 65%         | 90%         | > 25.9                | 90%         | 55% |  |
| Group III<br>(41-50) | > 27.9                | 75%         | 80%         | > 28.3                | 65%         | 90% |  |

Table 8: Bland & Altman Analysis for Inter-Observer Agreement for Maximum Ramus Breadth among Various Age Groups

| Age<br>Groups<br>(years) | Sample<br>Size | Arithmetic<br>Mean<br>(mm) | 95%<br>Confidence<br>Interval<br>(mm) | Lower<br>limit<br>(mm) | 95%<br>Confidence<br>Interval<br>(mm) | Upper<br>Limit<br>(mm) | 95%<br>Confidence<br>Inetrval<br>(mm) | p-value |
|--------------------------|----------------|----------------------------|---------------------------------------|------------------------|---------------------------------------|------------------------|---------------------------------------|---------|
| Group I                  | 40             | -1.03                      | -1.37                                 | -3.11                  | -3.70                                 | 1.05                   | 0.47                                  | <       |
| (21-30)                  |                |                            | to                                    |                        | to                                    |                        | to                                    | 0.0001  |
|                          |                |                            | -0.69                                 |                        | -2.53                                 |                        | 1.64                                  |         |
| Group II                 | 40             | -0.32                      | -0.72                                 | -2.79                  | -3.48                                 | 2.16                   | 1.46                                  | 0.122   |
| (31-40)                  |                |                            | to                                    |                        | to                                    |                        | to                                    |         |
|                          |                |                            | 0.09                                  |                        | -2.09                                 |                        | 2.85                                  |         |
| Group III                | 40             | -0.07                      | -0.49                                 | -2.63                  | -3.35                                 | 2.49                   | 1.77                                  | 0.727   |
| (41-50)                  |                |                            | to                                    |                        | to                                    |                        | to                                    |         |
|                          |                |                            | 0.35                                  |                        | -1.91                                 |                        | 3.20                                  |         |

Table 9: Bland & Altman Analysis for Inter-Observer Agreement for Minimum Ramus Breadth among Various Age Groups

| Age<br>Groups<br>(years) | Sample<br>Size | Arithmetic<br>Mean (mm) | 95%<br>Confidence<br>Interval<br>(mm) | Lower<br>limit<br>(mm) | 95%<br>Confidence<br>Interval<br>(mm) | Upper<br>Limit<br>(mm) | 95%<br>Confidence<br>Interval<br>(mm) | p-value  |
|--------------------------|----------------|-------------------------|---------------------------------------|------------------------|---------------------------------------|------------------------|---------------------------------------|----------|
| Group I                  | 40             | 0.94                    | 0.73                                  | -0.32                  | -0.67                                 | 2.19                   | 1.83                                  | < 0.0001 |
| (21-30)                  |                |                         | to                                    |                        | to                                    |                        | to                                    |          |
|                          |                |                         | 1.14                                  |                        | 0.04                                  |                        | 2.54                                  |          |
| Group II                 | 40             | 0.91                    | 0.76                                  | -0.04                  | -0.31                                 | 1.87                   | 1.60                                  | < 0.0001 |
| (31-40)                  |                |                         | to                                    |                        | to                                    |                        | to                                    |          |
|                          |                |                         | 1.07                                  |                        | 0.23                                  |                        | 2.14                                  |          |
| Group III                | 40             | 1.06                    | 0.87                                  | -0.12                  | -0.45                                 | 2.24                   | 1.91                                  | < 0.0001 |
| (41-50)                  |                | 1.00                    | to                                    | 0.12                   | to                                    | 2.27                   | to                                    |          |
|                          |                |                         | 1.25                                  |                        | 0.21                                  |                        | 2.57                                  |          |

Table 10: Bland & Altman Analysis for Inter-Observer Agreement for Condylar Height among Various Age Groups

| Age<br>Groups<br>(years) | Sample<br>Size | Arithmetic<br>Mean<br>(mm) | 95%<br>Confidence<br>Interval<br>(mm) | Lower<br>limit<br>(mm) | 95%<br>Confidence<br>Interval<br>(mm) | Upper<br>Limit<br>(mm) | 95%<br>Confidence<br>Interval<br>(mm) | p-value |
|--------------------------|----------------|----------------------------|---------------------------------------|------------------------|---------------------------------------|------------------------|---------------------------------------|---------|
| Group I<br>(21-30)       | 40             | -0.22                      | -0.66<br>to<br>0.22                   | -2.93                  | -3.69<br>to<br>-2.16                  | 2.49                   | 1.73<br>to<br>3.25                    | 0.326   |
| Group II<br>(31-40)      | 40             | 0.15                       | -0.20<br>to<br>0.49                   | -1.98                  | -2.58<br>to<br>-1.38                  | 2.28                   | 1.68<br>to<br>2.87                    | 0.396   |
| Group III<br>(41-50)     | 40             | 0.06                       | -0.36<br>to<br>0.47                   | -2.49                  | -3.20<br>to<br>-1.77                  | 2.61                   | 1.89<br>to<br>3.32                    | 0.781   |

Table 11: Bland & Altman Analysis for Inter-Observer Agreement for Projective Height of Ramus among Various Age Groups

| Age<br>Groups<br>(years) | Sample<br>Size | Arithmetic<br>Mean<br>(Mm) | 95%<br>Confidence<br>Interval<br>(Mm) | Lower<br>Limit<br>(Mm) | 95%<br>Confidence<br>Interval<br>(Mm) | Upper<br>Limit<br>(Mm) | 95%<br>Confidence<br>Interval<br>(Mm) | p-Value |
|--------------------------|----------------|----------------------------|---------------------------------------|------------------------|---------------------------------------|------------------------|---------------------------------------|---------|
| Group I<br>(21-30)       | 40             | -0.23                      | -0.56<br>To<br>0.10                   | -2.24                  | -2.80<br>To<br>-1.67                  | 1.78                   | 1.22<br>To<br>2.35                    | 0.168   |
| Group II<br>(31-40)      | 40             | 0.30                       | 0.10<br>To<br>0.49                    | -0.89                  | -1.23<br>To<br>-0.56                  | 1.48                   | 1.15<br>To<br>1.82                    | 0.004   |
| Group III<br>(41-50)     | 40             | -0.12                      | -0.54<br>To<br>0.31                   | -2.72                  | -3.45<br>To<br>-1.99                  | 2.49                   | 1.76<br>To<br>3.22                    | 0.587   |

Table 12: Bland & Altman Analysis for Inter-Observer Agreement for Coronoid Height among Various Age Groups

| Age<br>Groups<br>(years) | Sample<br>Size | Arithmetic<br>Mean<br>(mm) | 95%<br>Confidence<br>Interval<br>(mm) | Lower<br>limit<br>(mm) | 95%<br>Confidence<br>Interval<br>(mm) | Upper<br>Limit<br>(mm) | 95%<br>Confidence<br>Interval<br>(mm) | p-value  |
|--------------------------|----------------|----------------------------|---------------------------------------|------------------------|---------------------------------------|------------------------|---------------------------------------|----------|
| Group I                  | 40             | -0.01                      | -0.28                                 | -1.72                  | -2.20                                 | 1.71                   | 1.23                                  | 0.971    |
| (21-30)                  |                |                            | to                                    |                        | to                                    |                        | to                                    |          |
|                          |                |                            | 0.27                                  |                        | -1.24                                 |                        | 2.19                                  |          |
| Group II                 | 40             | 0.61                       | 0.33                                  | -1.14                  | -1.63                                 | 2.36                   | 1.87                                  | 0.0001   |
| (31-40)                  |                |                            | to                                    |                        | to                                    |                        | to                                    |          |
|                          |                |                            | 0.90                                  |                        | -0.65                                 |                        | 2.85                                  |          |
| Group III                | 40             | 0.65                       | 0.37                                  | -1.03                  | -1.50                                 | 2.32                   | 1.85                                  | < 0.0001 |
| (41-50)                  |                |                            | to                                    |                        | to                                    |                        | to                                    |          |
|                          |                |                            | 0.92                                  |                        | -0.56                                 |                        | 2.79                                  |          |

Table 13: Bland & Altman Analysis for Inter-Observer Agreement for Height of the Body of Mandible among Various Age Groups

| Age<br>Groups<br>(years) | Sample<br>Size | Arithmetic<br>Mean<br>(mm) | 95%<br>Confidence<br>Interval<br>(mm) | Lower<br>limit<br>(mm) | 95%<br>Confidence<br>Interval<br>(mm) | Upper<br>Limit<br>(mm) | 95%<br>Confidence<br>Interval<br>(mm) | p-value |
|--------------------------|----------------|----------------------------|---------------------------------------|------------------------|---------------------------------------|------------------------|---------------------------------------|---------|
| Group I<br>(21-30)       | 40             | -0.01                      | -0.12<br>to                           | -0.66                  | -0.84<br>to                           | 0.63                   | 0.45<br>to                            | 0.812   |
| (21-30)                  |                |                            | 0.09                                  |                        | -0.48                                 |                        | 0.82                                  |         |
| Group II<br>(31-40)      | 40             | 0.18                       | -0.02<br>to                           | -1.02                  | -1.36                                 | 1.38                   | 1.04<br>to                            | 0.071   |
| (31-40)                  |                |                            | 0.38                                  |                        | to<br>-0.68                           |                        | 1.72                                  |         |
| Group III                | 40             | 0.13                       | -0.00                                 | -0.68                  | -0.91                                 | 0.95                   | 0.72                                  | 0.051   |
| (41-50)                  |                |                            | to                                    |                        | to                                    |                        | to                                    |         |
|                          |                |                            | 0.27                                  |                        | -0.45                                 |                        | 1.18                                  |         |

Table 14: Prediction Accuracy for Various Parameters on Mandibular Ramus and Body Among Males and Females of Various Age Groups (Observer 1 & 2)

| S.No.  | PARAMETERS                        | Ob 1  |         |       | Ob 2  |         |       |
|--------|-----------------------------------|-------|---------|-------|-------|---------|-------|
| 0.140. | TAIVAVILILIO                      | Males | Females | Total | Males | Females | Total |
| 1.     | Maximum Ramus<br>Breadth          | 83.3% | 66.7%   | 75%   | 73.3% | 83.3%   | 78.3% |
| 2.     | Minimum Ramus<br>Breadth          | 85%   | 55%     | 70%   | 68.3% | 75%     | 71.7% |
| 3.     | Condylar Height                   | 93.3% | 81.7%   | 87.5% | 90%   | 90%     | 90%   |
| 4.     | Projective Height of<br>Ramus     | 95%   | 75%     | 85%   | 90%   | 81.7%   | 85.8% |
| 5.     | Coronoid Height                   | 83.3% | 86.7%   | 85%   | 88.3% | 83.3%   | 85.8% |
| 6.     | Height of the Body of<br>Mandible | 63.3% | 90%     | 76.7% | 81.7% | 68.3%   | 75%   |

Table 15: Comparison of Prediction Accuracy for Various Parameters on Mandibular Ramus and Body of the Mandible among Males and Females of Various Age Groups (Observer 1 & 2)

| C NI= | DADAMETERO           | Ob 1  |         |       | Ob 2  |         |       |
|-------|----------------------|-------|---------|-------|-------|---------|-------|
| S.No. | PARAMETERS           | Males | Females | Total | Males | Females | Total |
| 1.    | Mandibular Ramus     | 88%   | 73%     | 80.5% | 82%   | 82.7%   | 82.3% |
| 2.    | Body of the Mandible | 63.3% | 90%     | 76.7% | 81.7% | 68.3%   | 75%   |




Fig. 1: Image showing measurement from the reference lines drawn from the anatomic landmarks of the mandible. (Diagram showing mandibular ramus measurements adapted from Saini et al. (17))



Fig. 2: OPG image showing measurements taken on the right side of the mandible.



### Global Journal of Medical Research: J Dentistry & Otolaryngology

Volume 24 Issue 1 Version 1.0 Year 2024

Type: Double Blind Peer Reviewed International Research Journal

Publisher: Global Journals

Online ISSN: 2249-4618 & Print ISSN: 0975-5888

# Oral Complications in Cancer Patients: The Role of Chemotherapy and Radiotherapy

By Bárbara Maria de Souza Moreira Machado, Paula Cardoso Mascarenhas Xavier, Mariane Carolina Faria Barbosa, Leandro Araújo Fernandes, Daniela Coelho de Lima & Eduardo José Pereira Oliveira

Abstract- Objective: To evaluate the association between chemotherapy and radiotherapy with occurrence of oral complications in cancer patients.

Methods: This cross-sectional study included 399 adults in cancer treatment in a High Complexity Oncology Care Unit (HCOCU) in Minas Gerais, Brazil. Participants adults (> 18 years) were included in the study who undergoing treatment or are being monitored after treatment, at the Oncological Center of the Casa de Caridade Nossa Senhora do Perpétuo Socorro between 2017 and 2019. Outcomes were assessed through a questionnarie about self-reported oral complications, such as xerostomia, halitosis, taste changes, dietary modifications, trismus, mucositis, and the presence of infection/inflammation.

Keywords: chemotherapy, radiotherapy, oncology hospital services, oral health, questionnaires and surveys.

GJMR-J Classification: NLMC Code: QZ 241-260



Strictly as per the compliance and regulations of:



© 2024. Bárbara Maria de Souza Moreira Machado, Paula Cardoso Mascarenhas Xavier, Mariane Carolina Faria Barbosa, Leandro Araújo Fernandes, Daniela Coelho de Lima & Eduardo José Pereira Oliveira. This research/review article is distributed under the terms of the Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0). You must give appropriate credit to authors and reference this article if parts of the article are reproduced in any manner. Applicable licensing terms are at https://creativecommons.org/licenses/by-nc-nd/4.0/.

# Oral Complications in Cancer Patients: The Role of Chemotherapy and Radiotherapy

Bárbara Maria de Souza Moreira Machado a, Paula Cardoso Mascarenhas Xavier o, Mariane Carolina Faria Barbosa <sup>ρ</sup>, Leandro Araújo Fernandes <sup>ω</sup>, Daniela Coelho de Lima <sup>¥</sup> & Eduardo José Pereira Oliveira §

Abstract- Objective: To evaluate the association between chemotherapy and radiotherapy with occurrence of oral complications in cancer patients.

Methods: This cross-sectional study included 399 adults in cancer treatment in a High Complexity Oncology Care Unit (HCOCU) in Minas Gerais, Brazil. Participants adults (> 18 years) were included in the study who undergoing treatment or are being monitored after treatment, at the Oncological Center of the Casa de Caridade Nossa Senhora do Perpétuo Socorro between 2017 and 2019. Outcomes were assessed through a questionnarie about self-reported oral complications, such as xerostomia, halitosis, taste changes, dietary modifications, trismus, mucositis, and the presence of infection/inflammation. Oncological treatments were categorized as chemotherapy. chemotherapy/radiotherapy, radiotherapy. and Covariates included socioeconomic status, general health, and oral health. Associations were determined using multiple logistic regression models.

Results: The most common treatment was the combination of chemotherapy and radiotherapy (36.34%), while radiotherapy alone was the least common (13.78%). Among the oral changes after cancer treatment, the most prevalent were xerostomia (60.15%) and dietary changes (57.64%). Chemotherapy was associated with taste changes (OR: 2.44; 95% CI: 1.22-4.90). Chemotherapy and radiotherapy togheter were associated with greater odds of taste changes (OR: 3.86; 95% CI: 1.92-7.75) and mucositis (OR: 2.51; 95% CI: 1.06-5,94).

Conclusions: Patients undergoing chemotherapy alone or in combination with radiotherapy treatments were more prone to oral complications. This underscores the significance of dental care in promoting the well-being and quality of life for these patients.

Keywords: chemotherapy, radiotherapy, oncology hospital services, oral health, questionnaires and surveys.

#### Introduction

ental care is pivotal to the health of cancer patients. Both the disease itself and the therapeutic approaches used for treatment can give rise to oral complications<sup>1</sup>.

Considered the second leading cause of death in the world, cancer poses significant public health challenges due to its multifaceted nature and its epidemiological, social, and economic impacts. GLOBOCAN's 2020 estimates showed approximately 19 million new cancer cases worldwide, resulting in around 10 million deaths. In such a scenario, malignant tumors of the lung, breast, prostate, skin, and oral cavity, as well as hematological and lymphatic tumors, were identified as the most prevalent cancer types<sup>2</sup>. In the Brazilian context, cancer is also considered an important public health problem. During the 2020-2022 triennium, an estimated 625,000 new cancer cases were expected annually<sup>3,4</sup>.

Surgery, radiotherapy, chemotherapy, bone marrow transplantation, and targeted molecular therapy are commonly used, either in isolation or in combination, to treat cancer<sup>5</sup>. Advances in cancer treatments have contributed positively to the increase in survival and quality of life of these patients. Although there is no consensus on the best therapeutic approach for the treatment of cancer, it is notable that around 70% of patients undergo chemotherapy as their primary treatment<sup>6</sup>. However, chemotherapy's broad-spectrum toxicity affects not only neoplastic cells, but also healthy tissues, leading to oral complications and exacerbating pre-existing complications<sup>7</sup>. Furthermore, radiotherapy, is have reaching a utilization rate of 52% in the external irradiation modality, contributing to an increase in the patient's survival rate8.

Therefore, the clinical manifestations of cancer and the effects of oncological therapies on the patient's oral health warrant attention. In addition to oral and dental complications that include mucositis, infections, pain, salivary gland dysfunction, taste changes, dysphagia, trismus, and necrosis of soft and hard tissues<sup>9,10,11</sup>, patients can experience pronounced and swallowing impairments, speech changes, sensory deficits, and chronic pain<sup>12</sup>. Such issues can substantially affect patient quality of life and

Author  $\alpha \sigma \omega$  §: Dental School, Federal University of Alfenas (UNIFAL), Alfenas, (MG), Brazil.

Author p: Departament of Pediatric Dentistry, Federal University of Minas Gerais (UFMG), Belo Horizonte, (MG), Brazil.

Author ¥: Health Care Coordination - Alfenas Regional Superintendence, State Department of Health of Minas Gerais, Alfenas (MG), Brazil. e-mail: eduardooliveiraacustico@gmail.com

survival. It is estimated that approximately 40% of patients who receive radiotherapy and chemotherapy develop oral complications resulting from direct or indirect stomatotoxicity<sup>6</sup>. Even though radiotherapy, especially for head and neck cancers, which is a primary cause of oral complications, surgical procedures and chemotherapy can also induce or exacerbate dental and periodontal issues<sup>13</sup>.

Considering the toxicities arising from cancer therapeutic approaches for the soft and hard tissues of the oral region, oncological treatment may even be halted, resulting in harmful events, such as increased morbidity and decreased survival<sup>14</sup>. In this context, dental assessments, and adequate management of cancer patients throughout the treatment phases of the disease are crucial for a holistic and multidisciplinary approach to patient care 15,16,17 to eliminate or reduce the risk of such complications. Therefore, attention and knowledge regarding the prevention, diagnosis, and management of oral complications from oncological therapies are essential so that all health professionals, including dentists, can contribute to mitigating the impact of these complications on the patient's life<sup>18,19</sup> and, thereby, enhancing their quality of life, reducing adverse effects and local complications of oncological treatment, and promoting more prolonged survival.

Given these considerations complications the cancer itself and the for treatment can give rise to oral health, the aim of this study was to assess the association between oncological treatment types and the onset of oral complications in patients treated in a High Complexity Oncology Care Unit (HCOCU) in southern of the Minas Gerais state, Brazil.

#### II. Material and Methods

#### a) Ethical considerations

This study was submitted for evaluation by the Human Research Ethics Committee of the Federal University of Alfenas (UNIFAL-MG), being approved under opinion no. 2,487,546. Voluntary participation was consented to by signing the Informed Consent Form (ICF). The procedures used in this study adhere to the tenets of the Declaration of Helsinki and the Resolution 466, December 2012, of the Brazilian National Health Council, respecting the principles of the beneficence, non-maleficence, autonomy, confidentiality and justice.

#### b) Study design, setting, and participants

A cross-sectional study was conducted on a sample of patients assisted by the Associação dos Voluntários Vida Viva de Alfenas. The approached patients received treatment at the HCOCU of Santa Casa de Caridade Nossa Senhora do Perpétuo Socorro in Alfenas, MG, Brazil. This oncology center offers public treatments including chemotherapy, immunotherapy, hormone therapy, radiotherapy, and surgery, serving regions in southern Minas Gerais, Brazil. This region

covers 24 municipalities, being the reference for cancer treatment for a population of 437,005 inhabitants<sup>20</sup>. The Casa do Café of the Associação dos Voluntários Vida Viva was selected for this study because is the reference for the oncological patients attended in the southern region of Minas Gerais.

The minimum sample size was determined using the average DMFT (decayed, missing, and filled teeth) for the adult and elderly population<sup>21</sup>. This index is widely used as to produce a snapshot of the oral health conditions of the population as to parameterize sample size once caries and tooth loss are conditions with high dissemination and well described in many populations.<sup>21</sup> To this end, the equation proposed by Silva<sup>22</sup> was used:

$$n = \frac{Z^2. S^2. \operatorname{deff} / \operatorname{TNR}}{(\overline{X}. \varepsilon)^2}$$

where n refers to the final sample size; Z to the limit value of the rejection area, considering a certain level of significance (1.96 corresponding to 95% confidence); S^(2) to the DMFT<sup>21</sup> variance; deff (design effect design effect) = 3; TNR at non-response rate = estimated percentage of loss of sample elements - 20%;  $\overline{X}$ : average DMFT<sup>21</sup>;  $\varepsilon$  represents acceptable margin of error - 10%. The reference were the DMFT indexes for the population of adults living in cities in the countryside of Southeastern Brazil: mean (16.64) and standard deviation (8.04), obtained from the last national oral health survey - SB Brasil 2010<sup>21</sup>. A confidence level of 95% was established. This led to an estimated sample size of 309 subjects. The sampling process was random, being interviewed those who agreed to participate in the study were listed until the minimum sample size was reached, covering 399 cancer patients attending the Casa do Café of the Associação dos Voluntários Vida Viva de Alfenas. The inclusion criteria were: accepting participation in the study and expressing consent in the Informed Consent Form; attending the study's location - Casa do Café of the Associação dos Voluntários Vida Viva de Alfenas; undergoing treatment at the Oncological Center of the Casa de Caridade Nossa Senhora do Perpétuo Socorro during the period the study, between 2017 and 2019; being over 18 years old; having any cancer (not specific) or are being monitored after treatment for a neoplasm; and being able to communicate with the researcher.

#### c) Variables

self-reported Outcomes were oral complications, including xerostomia, halitosis, changes, dietary changes, trismus, mucositis, and presence of infection/inflammation.

The primary exposure was the type of oncological treatment adopted, classified as chemotherapy; radiotherapy: chemotherapy and radiotherapy: and others (surgical and/or drug treatment).

Covariates included socioeconomic factors health habits, general health, and oral health conditions. Socioeconomic factors included age; gender; education level ≤8 years of study/> 8 years of study). Health habits included current smoking and current drinking. General health conditions included multimorbidity (0-1 conditions/≥2 conditions); polypharmacy medications/≥4 medications); tumor location (other sites/head and neck); time of treatment (≤1 year/>1 vear): previous cancer (ves/no). Oral health conditions included number of teeth (0 to 9 teeth; 10 to 19 teeth; 20 or more teeth); prosthesis use; dental caries; gum bleeding; periodontal pockets; self-assessment of poor/very poor oral health (yes/no); oral health guidance received during oncology treatment (yes/no).

The blocks "socioeconomic factors", "general health", "health habits", "oral changes" and the variables "self-assessment of poor oral health" and "oral health guidance" from the "oral health" block were collected exclusively through interviews and recorded in a guestionnaire. The other variables in this block were assessed through intraoral physical examination. This examination was carried out under natural light, using a mouth mirror, gauze, and a ballpoint-type periodontal probe, following the criteria recommended by the World Health Organization (WHO)<sup>23,24</sup> by two duly trained examiners (B.M.S.M.M., and M.C.F.B.), and calibrated in a previous pilot study conducted with 20 patients at the same institution as the main study. Pilot study participants were not included in the main study. The inter-examiner agreement coefficient (Kappa) was 0.89, expressing good agreement<sup>23,24</sup>.

#### d) Data analysis

The descriptive analysis was carried out with estimates of measures of central tendency and its dispersion (for age) as well as absolute and relative frequencies, according to the type of oncological treatment. Associations between treatment types and other variables were determined using the chi-square test with Rao-Scott correction (Table 1).

For significant oral changes predicted by oncological treatment type (p<0.05) in Table 1, both crude and adjusted analyses were carried out using Logistic Regression models. Results were expressed using odds ratios (OR) and their respective 95% confidence intervals for detailing the risk of each of the oral changes, according to the oncological treatment type (chemotherapy; radiotherapy; chemotherapy and radiotherapy; others). The reference category was the "others" group. To define the variables listed as adjustment measures for the association between the oncological treatment type and oral changes, crude analyses of the association between the independent variables and the outcomes (oral changes) were

conducted, and those independent variables whose association showed p<0.05 in the crude analysis were inserted as adjustment measures (Table 2). It is important to highlight that only relevant conditions were considered in this study, according the literature.

The results were generated using the Stata 14.0 program (Stata Corp LLP, College Station, TX). For all procedures, a significance threshold of 5% (p<0.05) was adopted.

#### III. RESULTS

399 of the 1200 patients undergoing cancer treatment in the HCOCU in Alfenas, MG, Brazil between 2017 and 2019 were interviewed, exceeding the minimum required sample of 309 participants. In this way, it is possible to state that the sample was statistically representative of the study population. Table 1 describes the socioeconomic factors, health habits, general health, and oral health conditions, and oral changes following cancer treatment for the study participants. The average age of those interviewed at Casa do Café was 58.8 (±13.8) years. The sample included a majority of women (58.15%), people with low education levels (76.88% studied up to primary school), and low income (63.91% receive less than one monthly minimum wage). Health habits revealed 16.29% smokers and 13.03% reported regular consumption. The general health status of a quarter of patients undergoing cancer treatment is also affected by a set of other diseases (21.55% have two or more chronic conditions alongside cancer), with 22.50% of this population on at least four medications daily in the last three months. Head and neck tumors constituted 8.54% of cases, and most participants have been undergoing treatment for more than a year (61.79%).

Regarding oral health conditions, around half of the participants (49.62%) had severe tooth loss (between zero and nine remaining teeth), and 59.90% used prostheses. About one third of participants (31.83%) had active caries and the most prevalent periodontal condition was gingival bleeding with 84.71%. only 10.78% of the respondents rated their oral health as poor or very poor and only 13.03% received guidance about their oral health during cancer treatment. Regarding the oncological treatment type, the combination of chemotherapy and radiotherapy was most common (36.34%). Among the oral changes after cancer treatment, the most prevalent were xerostomia (60.15%) and dietary changes (57.64%). Oncological treatment types were associated with the occurrence of taste changes (p<0.001), dietary changes (p=0.001), and the occurrence of mucositis (p=0.002). Patients who underwent chemotherapy or chemotherapy associated with radiotherapy had more oral changes (taste changes, dietary changes, and mucositis).

Table 1: Characterization of the sample of cancer patients, according to the type of treatment received. Alfenas, MG, 2019. (continues)

|                                    | Total     |                | Type of cancer treatment Others Chemo Radio Chemo/Radio p-va |                |                |                   |        |  |
|------------------------------------|-----------|----------------|--|----------------|----------------|-------------------|--------|--|
|                                    |           |                | Others   | Chemo/Radio    | p-value        |                   |        |  |
|                                    | n         | %              | %  | %              | %              | %                 |        |  |
| Total                              | 399       | 100            | 17.29  | 32.58          | 13.78          | 36.34             |        |  |
| Socioeconomic conditio             | ns        |                |  |                |                |                   |        |  |
| Sex                                |           |                |  |                |                |                   |        |  |
| Man                                | 167       | 41.85          | 18.56  | 36.53          | 16.77          | 28.14             | 0.032  |  |
| Woman                              | 232       | 58.15          | 16.38  | 29.74          | 11.64          | 42.24             | 0.032  |  |
| Education level                    |           |                |  |                |                |                   |        |  |
| ≤8 years of study                  | 306       | 76.88          | 18.63  | 31.37          | 15.03          | 34.97             | 0.194  |  |
| >8 years of study                  | 92        | 23.12          | 11.96  | 36.96          | 9.78           | 41.30             | 0.194  |  |
| Income                             |           |                |  |                |                |                   |        |  |
| ≤1 minimum wage                    | 193       | 63.91          | 15.54  | 29.53          | 14.51          | 40.41             | 0.316  |  |
| >1 minimum wage                    | 109       | 36.09          | 14.68  | 39.45          | 10.09          | 35.78             | 0.010  |  |
| Health habits                      |           |                |  |                |                |                   |        |  |
| Current Smoking                    |           |                |  |                |                |                   |        |  |
| No                                 | 334       | 83.71          | 17.07  | 32.04          | 14.07          | 36.83             | 0.918  |  |
| Yes                                | 65        | 16.29          | 18.46  | 35.38          | 12.31          | 33.85             | 0.510  |  |
| Current alcohol                    |           |                |  |                |                |                   |        |  |
| No                                 | 347       | 86.97          | 17.58  | 32.85          | 13.54          | 36.02             | 0.946  |  |
| Yes                                | 52        | 13.03          | 15.38  | 30.77          | 15.38          | 38.46             | 0.940  |  |
| General Health                     |           |                |  |                |                |                   |        |  |
| Multimorbity                       |           |                |  |                |                |                   |        |  |
| 0-1 conditions                     | 313       | 78.45          | 14.70  | 34.19          | 14.38          | 36.74             | 0.005  |  |
| ≥2 conditions                      | 86        | 21.55          | 26.74  | 26.74          | 11.63          | 34.88             | 0.065  |  |
| Polipharmacy                       |           |                |  |                |                |                   |        |  |
| <4 medications                     | 279       | 77.50          | 16.49  | 32.26          | 13.26          | 37.99             | 0.004  |  |
| ≥4 medications                     | 81        | 22.50          | 23.46  | 34.57          | 14.81          | 27.16             | 0.264  |  |
| Tumor location                     |           |                |  |                |                |                   |        |  |
| Others sites                       | 364       | 91.46          | 16.71  | 34.25          | 13.70          | 35.34             | 0.457  |  |
| Head/neck                          | 34        | 8.54           | 21.21  | 15.15          | 15.15          | 48.48             | 0.157  |  |
| Time in treatment                  |           |                |  |                |                |                   |        |  |
| ≤1 year                            | 149       | 38.21          | 22.82  | 40.27          | 11.41          | 25.50             | -0.001 |  |
| >1 year                            | 241       | 61.79          | 13.28  | 27.80          | 14.94          | 43.98             | <0.001 |  |
| Previous câncer                    |           |                |  |                |                |                   |        |  |
| No                                 | 313       | 78.45          | 18.21  | 31.31          | 13.42          | 37.06             | 0.000  |  |
| Yes                                | 86        | 21.55          | 13.95  | 37.21          | 15.12          | 33.72             | 0.620  |  |
| Oral Health                        |           |                |  |                |                |                   |        |  |
| Number of teeth                    |           |                |  |                |                |                   |        |  |
|                                    | 198       | 49.62          | 17 17  | 21 21          | 1717           | 34.34             |        |  |
| 0 - 9 teeth<br>10 a-19 teeth       | 51        | 49.02<br>12.78 | 17.17<br>25.49   | 31.31<br>29.41 | 17.17<br>15.69 | 29.41             | 0.136  |  |
|                                    | 150       | 12.78<br>37.59 | 25.49<br>14.67   | 29.41<br>35.33 | 8.67           | 29.41<br>41.33    | 0.130  |  |
| 20 or more teeth Use of prosthesis | 130       | 37.39          | 14.07  | 33.33          | 0.07           | 41.33             |        |  |
| No                                 | 160       | 40.10          | 14.37  | 35.00          | 10.00          | 40.63             |        |  |
| Yes                                | 239       | 59.90          | 19.25  | 30.96          | 16.32          | 33.47             | 0.116  |  |
| Dental Caries                      | 239       | 39.90          | 19.23  | 30.90          | 10.32          | 33.47             |        |  |
| No                                 | 272       | 68.19          | 17.28  | 22.46          | 13.60          | 25.66             |        |  |
| Yes                                | 127       | 31.83          | 17.28<br>17.32   | 33.46<br>30.71 | 14.17          | 35.66<br>37.80    | 0.954  |  |
| Gum bleeding                       | 141       | 51.03          | 17.34  | 30.71          | 14.17          | 37.00             |        |  |
| No                                 | 338       | 84.71          | 17.46  | 32.54          | 14.79          | 35.21             |        |  |
| Yes                                | 556<br>61 | 15.29          | 16.39  | 32.79          | 8.20           | 42.62             | 0.485  |  |
| Periodontal pocket                 | ΟI        | 13.29          | 10.39  | 34.19          | 0.20           | <del>4</del> ∠.U∠ |        |  |
| No                                 | 330       | 82.71          | 17.58  | 30.61          | 13.94          | 37.88             |        |  |
| Yes                                | 69        | 82.71<br>17.29 | 17.58<br>15.94   | 42.03          | 13.94          | 28.99             | 0.302  |  |
| Poor oral health                   | 09        | 17.29          | 13.94  | 4 <u>८</u> .US | 13.04          | 20.99             |        |  |
| No                                 | 356       | 89.22          | 16.57  | 22.02          | 14.04          | 27.26             |        |  |
|                                    |           |                |  | 32.02          |                | 37.36<br>27.01    | 0.491  |  |
| Yes                                | 43        | 10.78          | 23.26  | 37.21          | 11.63          | 27.91             |        |  |

Table 1: Characterization of the sample of cancer patients, according to the type of treatment received. Alfenas, MG, 2019.

|                        |        | Total | Types of cancer treatment |       |       |             |             |  |
|------------------------|--------|-------|---------------------------|-------|-------|-------------|-------------|--|
|                        |        |       | Others                    | Chemo | Radio | Chemo/Radio | p-<br>value |  |
|                        | n      | %     | %                         | %     | %     | %           |             |  |
| Orientation in Oral    | Health |       |                           |       |       |             |             |  |
| No                     | 347    | 86.97 | 18.73                     | 32.85 | 14.99 | 33.43       | 0.0         |  |
| Yes                    | 52     | 13.03 | 7.69                      | 30.77 | 5.77  | 55.77       | 07          |  |
| Oral changes           |        |       |                           |       |       |             |             |  |
| Xerostomia             |        |       |                           |       |       |             |             |  |
| No                     | 159    | 39.85 | 18.87                     | 29.56 | 14.47 | 37.11       | 0.7         |  |
| Yes                    | 240    | 60.15 | 16.25                     | 34.58 | 13.33 | 35.83       | 41          |  |
| Halitosis              |        |       |                           |       |       |             |             |  |
| No                     | 291    | 72.93 | 17.87                     | 34.02 | 15.12 | 32.99       | 0.1         |  |
| Yes                    | 108    | 27.07 | 15.74                     | 28.70 | 10.19 | 45.37       | 33          |  |
| Change in taste        |        |       |                           |       |       |             |             |  |
| No                     | 208    | 52.13 | 23.56                     | 32.69 | 15.38 | 28.37       | <0.         |  |
| Yes                    | 191    | 47.87 | 10.47                     | 32.46 | 12.04 | 45.03       | 001         |  |
| Dietary changes        |        |       |                           |       |       |             |             |  |
| No                     | 169    | 42.36 | 23.08                     | 24.85 | 18.34 | 33.73       | 0.0         |  |
| Yes                    | 230    | 57.64 | 13.04                     | 38.26 | 10.43 | 38.26       | 01          |  |
| Lockjaw                |        |       |                           |       |       |             |             |  |
| No                     | 332    | 83.21 | 17.47                     | 33.43 | 13.55 | 35.54       | 0.8         |  |
| Yes                    | 67     | 16.79 | 16.42                     | 28.36 | 14.93 | 40.30       | 26          |  |
| Mucositis              |        |       |                           |       |       |             |             |  |
| No                     | 262    | 65.83 | 20.23                     | 32.06 | 16.79 | 30.92       | 0.0         |  |
| Yes                    | 136    | 34.17 | 11.76                     | 33.82 | 8.09  | 46.32       | 02          |  |
| Inflammation/infection | n      |       |                           |       |       |             |             |  |
| No                     | 300    | 75.19 | 18.33                     | 30.67 | 15.67 | 35.33       | 0.1         |  |
| Yes                    | 99     | 24.81 | 14.14                     | 38.38 | 8.08  | 39.39       | 35          |  |

Table 2 displays the crude and adjusted Logistic Regression models for oral changes and oncological treatment types. Radiotherapy alone didn't show any associations, whereas chemotherapy was associated to an increased likelihood of taste changes (OR: 2.44; 95% CI: 1.22-4.90). Chemotherapy and

radiotherapy together were associated with more odds of taste changes (OR: 3.86; 95% CI: 1.92-7.75) and mucositis (OR: 2.51; 95% CI: 1.06-5. 94), independently of socioeconomic factors, health habits, general health, and oral health conditions.

Table 2: Crude and adjusted analyzes of the associations between type of cancer treatment and oral changes among cancer patients. Alfenas, MG, 2019.

|                           | Chemotherap      | ру    | Radiotherap       | у     | Chemo/Radio      |        |  |
|---------------------------|------------------|-------|-------------------|-------|------------------|--------|--|
|                           | OR (CI95%)       | р     | OR (Cl95%)        | р     | OR (CI95%)       | р      |  |
| Change in taste           |                  |       |                   |       |                  |        |  |
| An. Crude                 | 2,23 (1,20-4,17) | 0,012 | 1,76 (0,83- 3,71) | 0,137 | 3,57 (1,93-6,62) | <0,001 |  |
| An. Adjusted <sup>1</sup> | 2,44 (1,22-4,90) | 0,011 | 2,07 (0,91-4,73)  | 0,084 | 3,86 (1,92-7,75) | <0,001 |  |
| Dietary changes           |                  |       |                   |       |                  |        |  |
| An. Crude                 | 2,72 (1,49-4,97) | 0,001 | 1,01 (0,49-2,06)  | 0,986 | 2,01 (1,12-3,60) | 0,019  |  |
| An. Adjusted <sup>2</sup> | 2,08 (0,90-4,78) | 0,084 | 0,71 (0,25-2,00)  | 0,515 | 2,18 (0,95-5,00) | 0,066  |  |
| MUCOSITIS                 |                  |       |                   |       |                  |        |  |
| An. Crude                 | 1,81 (0,93-3,53) | 0,079 | 0,83 (0,35-1,97)  | 0,669 | 2,58 (0,17-0,53) | <0,001 |  |
| An. Adjusted <sup>3</sup> | 1,96 (0,80-4,81) | 0,140 | 0,74 (0,23-2,38)  | 0,614 | 2,51 (1,06-5,94) | 0,036  |  |

OR: odds ratio; CI95%: 95% confidence interval.

<sup>&</sup>lt;sup>1</sup>Model adjusted for: age, sex, polypharmacy, tumor site, number of teeth, use of prosthesis, self-assessment of oral health, oral health guidance received in Oncology;

<sup>&</sup>lt;sup>2</sup>Model adjusted for: age, education, income, alcohol, polypharmacy, tumor location, treatment time, scholarship, oral health selfassessment, oral health guidance received in Oncology;

<sup>&</sup>lt;sup>3</sup>Model adjusted for: age, sex, education, income, alcohol, tumor location, number of teeth, oral health guidance received in Oncology.

#### IV. Discussion

This study contributes to understanding the association between different cancer treatment types and oral complications. Their findings indicate that the most prevalent oral changes after cancer treatment are xerostomia and dietary changes. Furthermore, chemotherapy is associated with more odds of taste changes, whereas the combination of chemotherapy and radiotherapy is associated with taste changes and mucositis. These findings can contribute to a better approaching of the cancer patients as oncological scenario as in oral health management.

Among the oral complications after cancer treatment, the study showed that xerostomia (60.15%) and dietary changes (57.64%) were the most prevalent. Such data aligns with existing literature on the topic. In previous studies, Floriano et al.25 showed that xerostomia (71.9%), mucositis (67.7%), and candidiasis (32.3%) were the most common oral lesions after cancer treatment. Freire et al.<sup>26</sup> highlighted xerostomia (53.8%) as the most common oral manifestation, followed by purpura (15.4%), gingival bleeding (7.7%), periodontitis (7, 7%), thrombocytopenia (7.7%) and granulocytopenia (7.7%). Araújo et al.27 identified in their study that xerostomia (21.0%) and mucositis (12.3%) were the most common manifestations during cancer treatment. However, the researchers observed that, in participants who had completed treatment between 2-5 years prior, the prevalence of xerostomia and mucositis was similar. In patients who had completed treatment more than five years earlier, only xerostomia was identified (8.8%), and no other oral manifestations which suggests that some oral manifestations of cancer treatment can attenuate along time. However, it must not be ignored the permanent oral problems resulted. Amaral et al.28 also observed that the most identified oral complications were xerostomia (60.3%), mucositis (39.7%), and burning mouth syndrome (27.9%). Faza and Brun<sup>29</sup> observed that the most common complications were xerostomia, taste changes, and aphthous lesions. Considering xerostomia as the most prominent oral disorder, as in this study, Paiva and Biase<sup>30</sup> point out that it remains at a high incidence even after treatment has ended, as, in addition to the transitory decrease in saliva production, some therapeutic agents are capable of causing irreversible damage to glandular acini leading to lasting severe salivary dysfunction. Floriano et al. 25 warn that such conditions may be due to the lack of dental treatment both before oncological therapy, as well as during and after treatment, highlighting the importance of dental treatment or follow-up. Thus, Araújo et al.<sup>27</sup> reinforce the participation of the dentist during and after antineoplastic treatment. For Faza and Brun<sup>29</sup>, the role of dental professionals in the multidisciplinary cancer treatment team is evident, both in the initial phases during the course of therapy and

after the end of treatment, to guarantee a better quality of life. This is a special issue when considering that many of these oral complications can be prevented or even better managed in order to reduce losses in oral health, general health and quality of life of these patients.

This study showed that radiotherapy was not associated with any oral changes while chemotherapy resulted in greater odds of taste changes. However, chemotherapy and radiotherapy together were associated with greater odds of taste changes and mucositis. This result is consistent with the findings of Araújo et al.27, who noted a greater occurrence of oral when the manifestations patient underwent chemotherapy associated with radiotherapy when compared to individuals who underwent only one of these therapies. It must be considered that chemotherapy is the most widely adopted treatment for cancer, and this may contribute to its association with oral complications<sup>28,29</sup>. Despite radiotherapy not being directly associated with any of the oral changes observed in this study, the literature points out that radiotherapy causes disturbances in the integrity and function of the patient's oral cavity, leading to the development of oral complications. Gaetti-Jardim Júnior<sup>31</sup>, in a study carried out with patients undergoing head and neck radiotherapy, observed the presence of xerostomia, mucositis, and other side effects. Patients irradiated shortly after the start of radiotherapy develop severe mucositis, dermatitis, dysgeusia, xerostomia, and, to a lesser extent, candidiasis. After completion of radiotherapy, 68% of patients had grade III or IV mucositis. It was also found that the development of mucositis makes oral hygiene difficult, exacerbating inflammation in periodontal tissues. At the end of the study, the researchers concluded that the primary cause of radiotherapy abandonment as well as the severity of the sequelae depends on the oral conditions of the patients before starting treatment and the lack of dental treatment prior to oncological treatment. Braam et al.32 agree that radiotherapy, whether applied alone or in conjunction with chemotherapy or surgery, can induce significant immediate and long-term side effects to the oral cavity. These effects range from xerostomia and challenges with chewing and swallowing to impaired taste and a heightened risk of tooth decay or oral candidiasis. Based on this assumption, the researchers carried out a study to describe long-term changes in quality of life and its correlation with parotid salivary output in patients with head and neck cancer who underwent radiotherapy. Upon concluding their study, the researchers observed an improvement in the qualityof-life score related to xerostomia post-radiotherapy. In short, radiotherapy has been identified as a frequent cause of xerostomia, affecting 70% to 100% of patients treated with this therapeutic modality, worsening xerostomia and mucositis, as well as the occurrence of radiation-induced cavities<sup>29</sup>, causing devastating effects on the oral cavity. Such effects often complicate the continuation of radiotherapy procedures 31,32,33,34, as well as negatively influence the quality of life of cancer patients<sup>31,35,36,37,38</sup>. Nonetheless, the magnitude of such complications depends on a series of factors related to the treatment, the tumor, and the patient<sup>30</sup>. This may partially explain the lack of association between radiotherapy and oral changes in this study, especially given that only 13% of our sample was subjected exclusively to radiotherapy.

Chemotherapy frequently emerges as the primary treatment option, either as a standalone or in combination with radiotherapy and other treatments<sup>3,8</sup>. The choice of treatment method depends on factors such as the nature, extent, and location of the tumor and the patient's health conditions. As therapies that can be performed alone or in combination with other modalities, as observed in this study, chemotherapy and radiotherapy can damage the patient's oral cavity during and after treatment. This accentuates the pivotal role of dental professionals in conducting pre-treatment evaluations and overseeing care throughout and after the cancer treatment. Therefore, it is expected that the combination of chemotherapy and radiotherapy can in fact amplify potential adverse outcomes, precipitating the onset of oral complications.

It should be noted that the present study has limitations, such as the cross-sectional design, which did not allow inference regarding the sequence of events investigated. Therefore, it was not possible to determine precisely which occurred first: the oncological treatment or the oral problems. However, it is useful to clinical purposes to identify and describe such correlations in order to prevent some of these oral manifestations as well as to provide a better management and treatment. Furthermore, oral changes were investigated based on the subjects' self-report, which conditioned the investigation on the patients' memory and perception of their own health. It should also be noted that despite the robustness of the study design and sample determination, patients who expressed interest participated in the study, and it was not possible to carry out a draw to choose potential participants. This constraint arose from the specific characteristics of the study site, as well as the health status and availability of the patients. However, strengths include collecting data from patients with tumors from different locations, representing a health region with more than 400,000 inhabitants. This is because the oncology center that served as the population base for carrying out the study is the only one to provide oncological treatment via public health system in the specified region. Additionally, it is important to mention that oncological treatment is predominantly performed in public health system in Brazil<sup>3</sup>. Moreover, the study employed an adequate sample size, using instruments and techniques widely recognized internationally<sup>39,40</sup> to evaluate the conditions investigated. Future studies should explore in greater depth the associations and non-associations observed here, particularly the lack of association between radiotherapy and oral complications based on clinical data as well as to investigate how these complications can impact daily lives of the patients by means tools assessing quality of life.

#### Conclusion

Antineoplastic treatment is recognized as being associated with oral manifestations. Patients undergoing chemotherapy or the combination of chemotherapy and radiotherapy are more susceptible to oral problems, such as mucositis, taste changes, and dietary changes. Cancer patients must be monitored before, during, and after antineoplastic therapy by a dentist, included in a multidisciplinary team, to offer a holistic approach to patient care and prevent and control the occurrence of such complications. Options of treatment with reduced negative impact on oral health and well-being of the patients should be encouraged towards the view of the continuity between oral and general health, and, thus, assist the effectiveness of treatment, as well as promoting good health, well-being, and quality of life for these patients.

Authors Contributions

B.M.S.M.M., P.C.M.X., and M.C.F.B. participated in data collection and e databank interpretation, B.M.S.M.M. drafted and critically revised the manuscript. L.A.F., E.J.P.O., and D.C.L participated in conception and study design. E.J.P.O. participated in databank construction and interpretation. All authors reviewed and approved the final version of the manuscript.

Conflicts of Interests/Competing Interests The authors declare having no conflicts of interest.

**Funding** 

This study was funded by Universidade Federal de Alfenas (UNIFAL - Federal University of Alfenas) and the following Brazilian fostering agency: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES - Coordination for the Advancement of Higher Education Personnel - COD 001).

#### References Références Referencias

- Epstein, J. B., Thariat, J., Bensadoun, R. J., Barasch, A., Murphy, B. A., Kolnick, L., Popplewell, L., & Maghami, E. (2012). Oral complications of cancer and cancer therapy: from cancer treatment to survivorship. CA: A Cancer Journal for Clinicians, 62(6), 400-4221.
- Oliveira, M. C. Q., Lebre Martins, B. N. F., Santos-Silva, A. R., Rivera, C., Vargas, P. A., Lopes, M. A.,

- Vechiato-Filho, A. J., Brandão, T. B., & Padro-Ribeiro, A. C. (2020). Dental treatment needs in hospitalized cancer patients: a retrospective cohort Supportive Care in Cancer, 28(7), 3451-34572.
- Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA). (2021). Tratamento do câncer. Disponível em: https://www.inca.gov.br/tratamento/ quimioterapia#main-content. Acesso em abr. 2022.
- Lavor, A. (2020). Câncer: 625 mil novos casos por ano. RADIS, 210, 10-11.
- Algahtani, A. S., Alshamrani, Y., Alhazmi, Y., & Halboub, E. (2021). Complicações orais e dentárias da radioterapia para câncer de cabeça e pescoço: conhecimento de dentistas na Arábia Saudita. Asian Pacific Journal of Cancer Prevention, 22(7), 2033-2041.
- 6. Hespanhol, F. L., Tinoco, E. M. B., Teixeira, H. G. C., Falabella, M. E. V., & Assis, N. M. S. P. (2010). Manifestações bucais em pacientes submetidos à quimioterapia. Ciência & Saúde Coletiva, 15(1), 1085-1094.
- 7. Paiva, C. I., Zanatta, F. B., Flores, D. M., Pitthan, S. A., Dotto, G. N., & Chagas, A. M. (2004). Efeitos da quimioterapia na cavidade bucal. Disciplinarum Scientia, Série: Ciências da Saúde, Santa Maria, 4(1), 109-119.
- Delaney, G., Jacob, S., Featherstone, C., & Barton, M. (2005). The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer, 104(6), 1129-1137.
- Boñar-Álvarez, P., Padin-Iruegas, E., Chamorro-Petronacci, C., Gandara-Vila, P., Lorenzo-Pous, A. I., Somoza-Mmartin, M., Blanco-Carrión, A., García-García, A., & Perez-Sayans, M. (2021). Assessment of saliva and oral candidiasis levels 12, 24 and 36 months after radiotherapy in patients with head and neck cancer. Journal of Stomatology, Oral and Maxillofacial Surgery, 122(6), 566-572.
- 10. Brook. I. (2020). Late side effects of radiation treatment for head and neck cancer. Radiation Oncology Journal, 38(2), 84-921.
- 11. Martinez, A. C., Silva, I., Berti Couto, S. A., Gandra, R. F., Rosa, E. A. R., Johann, A. C. B. R., & Couto Souza, P. H. (2020). Late oral complications caused by head and neck radiotherapy: clinical and laboratory study. Journal of Oral and Maxillofacial Research, 11(3), e3.
- 12. Valdez, J. A., & Brennan, M. T. (2018). Impact of Oral Cancer on Quality of Life. Dental Clinics of North America, 62(1), 143-154.
- 13. Jorewicz, L. (2013). Managing dental complications in patients with head and neck cancer. Oncology, 58(1), 11-12.
- 14. Jasmer, K. J., Gilman, K. E., Muñoz Forti, K., Weisman, G. A., & Limesand, K. H. (2020).

- Radiation-induced salivary gland dysfunction: mechanisms, therapeutics, and future directions. Journal of Clinical Medicine, 9(12), 4095.
- 15. Bacher, H., Schweyen, R., Kuhnt, T., Leplow, B., & Hey, J. (2020). Use of a patient information leaflet on oro-dental care during radiotherapy. Patient Preference and Adherence, 14, 1751-1759.
- 16. Colloc, T., Brown, T., & Keys, W. (2020). Role of the consultant in restorative dentistry in managing head and neck cancer patients undergoing radiotherapy: a novel intraoral shield appliance design. British Dental Journal, 229(10), 655-660.
- 17. Moore, C., McLister, C., O'Neill, C., Donnelly, M., & McKenna, G. (2020). Pre-radiotherapy dental extractions in patients with head and neck cancer: a Delphi study. Journal of Dentistry, 97, 103350.
- 18. Cho, H., & Kumar, N. (2019). Dental management of a patient with head and neck cancer: a case report. British Dental Journal, 227(1), 25-29.
- 19. McCaul, L. K. (2012). Oral and dental management for head and neck cancer patients treated by chemotherapy and radiotherapy. Dentistry Update, 39(2), 135-138, 140.
- 20. Santa Casa de Alfenas. (Centro de Oncologia). (n.d.). Serviços. Disponível em: https://www. santacasaalfenas.com.br/centrodeoncologia. Acesso em abr. 2022.
- 21. Brasil. Ministério da Saúde. Secretaria de Atenção à Saúde. Secretaria de Vigilância em Saúde. (2012). SB Brasil 2010: Pesquisa Nacional de Saúde Bucal: resultados principais. Brasília: Ministério da Saúde.
- 22. Silva, N. N. (1998). Amostragem probabilística: um curso introdutório. São Paulo: EDUSP.
- 23. World Health Organization (WHO). (1997). Oral health surveys: basic methods (4th ed.). Geneva: ORH/EPID.
- 24. Oliveira, A. G. R. C., Unfer, B., Costa, I. C. C., Arcieri, R. M., Guimarães, L. O. C., & Saliba, N. A. (1998). Levantamentos epidemiológicos em saúde análise metodológica proposta Organização Mundial da Saúde. Revista Brasileira de Epidemiologia, 1(2), 177-189.
- 25. Floriano, D. F., Ribeiro, P. F. A., Maragno, A. C., Rossi, K., & Simões, P. W. T. A. (2017). Complicações orais em pacientes tratados com radioterapia ou quimioterapia em um hospital de Catarina. Revista Odontológica Universidade Cidade de São Paulo, 29(3), 230-236.
- 26. Freire, A. A. S., Honorato, P. S. M., Macedo, S. B., & Araújo, C. S. (2016). Bucal manifestations in patients submitted to chemotherapeutic treatment in the cancer hospital of Acre. Journal of the American Health Sciences, 2(1), 1-21.
- 27. Araújo, W. A. F., Rocha, I. O., Carneiro, G. K. M., & Garcia, N. G. (2021). Manifestações bucais em pacientes oncológicos. Revista Odontológica Brasileira Central, 30(89), 85-96.

- 28. Amaral, B. B., Sampaio, N. L. L. M., Duarte Filho, E. S. D., Peixoto, R. F., Carvalho, M. V., & Ferreira, S. J. (2021). Oral changes and quality of life of patients under chemotherapy treatment. RSBO, 18(2), 235-242.
- 29. Souza, J. F. G., & Brum, S. C. (2018). The influence of chemotherapy on oral health. Revista Pró-UniverSUS, 09(2), 81-89,
- 30. Jesus, L. G., Cicchelli, M., Martins, G. B., Pereira, M. C. C., Lima, H. S., & Medrado, A. R. A. P. (2016). Oral effects of anticancer drugs: a literature review. RFO - Revista da Faculdade de Odontologia, 21(1), 130-135.
- 31. Gaetti-Jardim Júnior, E., Sousa, F. R. N., Gaetti-Jardim, E. C., Castro, E. V. F. L., Ciesielski, F. I. N., Buso-Ramos, M. M., Okamoto, A. C., Crivelini, M. M., & Castro, A. L. (2011). Efeitos da radioterapia sobre as condições bucais de pacientes oncológicos. RPG - Revista Pós-Graduação, 18(2), 96-101.
- 32. Braam, P. M., Roesink, J. M., Raaijmakers, C. P., Busschers, W. B., & Terhaard, C. H. (2007). Quality of life and salivary output in patients with head-andneck cancer five years after radiotherapy. Radiation Oncology, 2, 3.
- 33. Kakoei, S., Haghdoost, Α. A., Rad, Mohammadalizadeh, S., Pourdamghan, N.. Nakhaei, M., & Bahador, M. (2012). Xerostomia after radiotherapy and its effect on quality of life in head and neck cancer patients. Archives of Iranian Medicine, 15(4), 214-218.
- 34. Wang, Z. H., Yan, C., Zhang, Z. Y., Zhang, C. P., Hu, H. S., Tu, W. Y., Kirwan, J., & Mendenhall, W. M. Outcomes xerostomia (2014).and postoperative radiotherapy for oral and oropharyngeal carcinoma. Head & Neck, 36(10), 1467-1473.
- 35. Pinna, R., Campus, G., Cumbo, E., Mura, I., & Milia, E. (2015). Xerostomia induced by radiotherapy: an overview of the physiopathology, clinical evidence, and management of the oral damage. Therapeutics and Clinical Risk Management, 11, 171-188.
- 36. Paterson, C., Caldwell, B., Porteous, S., McLean, A., & Thomson, Messow, C. M., Μ. (2016).Radiotherapy-induced xerostomia, pre-clinical promise of LMS-611. Supportive Care in Cancer, 24(2), 629-636.
- 37. Dijkema, T., Raaijmakers, C. P. J., Braam, P. M., Roesink, J. M., Monninkhof, E. M., & Terhaard, C. H. (2012). Xerostomia: a day and night difference. Radiotherapy and Oncology, 104(2), 219-223.
- 38. Tribius, S., Sommer, J., Prosch, C., Bajrovic, A., Muenscher, A., Blessmann, M., Kruell, A., Petersen, C., Todorovic, M., & Tennstedt, P. (2013). Xerostomia after radiotherapy. What matters-mean total dose or dose to each parotid gland? Strahlentherapie und Onkologie, 189(3), 216-222.

- 39. Brasil. Ministério da Saúde. Secretaria de Atenção à Saúde. Secretaria de Vigilância em Saúde. (2012). SB Brasil 2010: Pesquisa Nacional de Saúde Bucal: resultados principais. Brasília: Ministério da Saúde.
- 40. Organização Mundial da Saúde. (2017).Levantamentos em saúde bucal: métodos básicos (5ª ed.). São Paulo: Faculdade de Odontologia Universidade de São Paulo (FOUSP).


# Global Journals Guidelines Handbook 2024

www.GlobalJournals.org

### **MEMBERSHIPS**

#### FELLOWS/ASSOCIATES OF MEDICAL RESEARCH COUNCIL

#### FMRC/AMRC MEMBERSHIPS



#### INTRODUCTION

FMRC/AMRC is the most prestigious membership of Global Journals accredited by Open Association of Research Society, U.S.A (OARS). The credentials of Fellow and Associate designations signify that the researcher has gained the knowledge of the fundamental and high-level concepts, and is a subject matter expert, proficient in an expertise course covering the professional code of conduct, and follows recognized standards of practice. The credentials are designated only to the researchers, scientists, and professionals that have been selected by a rigorous process by our Editorial Board and Management Board.

Associates of FMRC/AMRC are scientists and researchers from around the world are working on projects/researches that have huge potentials. Members support Global Journals' mission to advance technology for humanity and the profession.

#### **FMRC**

#### FELLOW OF MEDICAL RESEARCH COUNCIL

FELLOW OF MEDICAL RESEARCH COUNCIL is the most prestigious membership of Global Journals. It is an award and membership granted to individuals that the Open Association of Research Society judges to have made a 'substantial contribution to the improvement of computer science, technology, and electronics engineering.

The primary objective is to recognize the leaders in research and scientific fields of the current era with a global perspective and to create a channel between them and other researchers for better exposure and knowledge sharing. Members are most eminent scientists, engineers, and technologists from all across the world. Fellows are elected for life through a peer review process on the basis of excellence in the respective domain. There is no limit on the number of new nominations made in any year. Each year, the Open Association of Research Society elect up to 12 new Fellow Members.



#### BENEFIT

#### TO THE INSTITUTION

#### GET LETTER OF APPRECIATION

Global Journals sends a letter of appreciation of author to the Dean or CEO of the University or Company of which author is a part, signed by editor in chief or chief author.



#### **EXCLUSIVE NETWORK**

#### GET ACCESS TO A CLOSED NETWORK

A FMRC member gets access to a closed network of Tier 1 researchers and scientists with direct communication channel through our website. Fellows can reach out to other members or researchers directly. They should also be open to reaching out by other.

Career

Credibility

Exclusive

Reputation



#### **CERTIFICATE**

#### CERTIFICATE, LOR AND LASER-MOMENTO

Fellows receive a printed copy of a certificate signed by our Chief Author that may be used for academic purposes and a personal recommendation letter to the dean of member's university.

Career

Credibility

Exclusive

Reputation



#### **DESIGNATION**

#### GET HONORED TITLE OF MEMBERSHIP

Fellows can use the honored title of membership. The "FMRC" is an honored title which is accorded to a person's name viz. Dr. John E. Hall, Ph.D., FMRC or William Walldroff, M.S., FMRC.

Career

Credibility

Exclusive

Reputation

#### RECOGNITION ON THE PLATFORM

#### BETTER VISIBILITY AND CITATION

All the Fellow members of FMRC get a badge of "Leading Member of Global Journals" on the Research Community that distinguishes them from others. Additionally, the profile is also partially maintained by our team for better visibility and citation. All fellows get a dedicated page on the website with their biography.

Career

Credibility

Reputation



#### **FUTURE WORK**

#### GET DISCOUNTS ON THE FUTURE PUBLICATIONS

Fellows receive discounts on the future publications with Global Journals up to 60%. Through our recommendation programs, members also receive discounts on publications made with OARS affiliated organizations.

Career

Financial



## GJ Internal Account

Unlimited forward of Emails

Fellows get secure and fast GJ work emails with unlimited storage of emails that they may use them as their primary email. For example, john [AT] globaljournals [DOT] org.

Career

Credibility

Reputation



#### PREMIUM TOOLS

#### ACCESS TO ALL THE PREMIUM TOOLS

To take future researches to the zenith, fellows receive access to all the premium tools that Global Journals have to offer along with the partnership with some of the best marketing leading tools out there.

Financial

#### **CONFERENCES & EVENTS**

#### ORGANIZE SEMINAR/CONFERENCE

Fellows are authorized to organize symposium/seminar/conference on behalf of Global Journal Incorporation (USA). They can also participate in the same organized by another institution as representative of Global Journal. In both the cases, it is mandatory for him to discuss with us and obtain our consent. Additionally, they get free research conferences (and others) alerts.

Career

Credibility

Financial

#### EARLY INVITATIONS

#### EARLY INVITATIONS TO ALL THE SYMPOSIUMS, SEMINARS, CONFERENCES

All fellows receive the early invitations to all the symposiums, seminars, conferences and webinars hosted by Global Journals in their subject.

Exclusive





#### PUBLISHING ARTICLES & BOOKS

#### EARN 60% OF SALES PROCEEDS

Fellows can publish articles (limited) without any fees. Also, they can earn up to 70% of sales proceeds from the sale of reference/review books/literature/publishing of research paper. The FMRC member can decide its price and we can help in making the right decision.

Exclusive

Financial

#### REVIEWERS

#### GET A REMUNERATION OF 15% OF AUTHOR FEES

Fellow members are eligible to join as a paid peer reviewer at Global Journals Incorporation (USA) and can get a remuneration of 15% of author fees, taken from the author of a respective paper.

Financial

#### ACCESS TO EDITORIAL BOARD

#### BECOME A MEMBER OF THE EDITORIAL BOARD

Fellows and Associates may join as a member of the Editorial Board of Global Journals Incorporation (USA) after successful completion of three years as Fellow and as Peer Reviewer.

Career

Credibility

Exclusive

Reputation

#### AND MUCH MORE

#### GET ACCESS TO SCIENTIFIC MUSEUMS AND OBSERVATORIES ACROSS THE GLOBE

All members get access to 5 selected scientific museums and observatories across the globe. All researches published with Global Journals will be kept under deep archival facilities across regions for future protections and disaster recovery. They get 10 GB free secure cloud access for storing research files.



### **AMRC**

#### ASSOCIATE OF MEDICAL RESEARCH COUNCIL

ASSOCIATE OF MEDICAL RESEARCH COUNCIL is the membership of Global Journals awarded to individuals that the Open Association of Research Society judges to have made a 'substantial contribution to the improvement of computer science, technology, and electronics engineering.

The primary objective is to recognize the leaders in research and scientific fields of the current era with a global perspective and to create a channel between them and other researchers for better exposure and knowledge sharing. Members are most eminent scientists, engineers, and technologists from all across the world. Associate membership can later be promoted to Fellow Membership. Associates are elected for life through a peer review process on the basis of excellence in the respective domain. There is no limit on the number of new nominations made in any year. Each year, the Open Association of Research Society elect up to 12 new Associate Members.



#### BENEFIT

#### TO THE INSTITUTION

#### GET LETTER OF APPRECIATION

Global Journals sends a letter of appreciation of author to the Dean or CEO of the University or Company of which author is a part, signed by editor in chief or chief author.



#### **EXCLUSIVE NETWORK**

#### GET ACCESS TO A CLOSED NETWORK

A AMRC member gets access to a closed network of Tier 2 researchers and scientists with direct communication channel through our website. Associates can reach out to other members or researchers directly. They should also be open to reaching out by other.

Career

Credibility

Exclusive

Reputation



#### CERTIFICATE

#### CERTIFICATE, LOR AND LASER-MOMENTO

Associates receive a printed copy of a certificate signed by our Chief Author that may be used for academic purposes and a personal recommendation letter to the dean of member's university.

Career

Credibility

Exclusive

Reputation



#### DESIGNATION

#### GET HONORED TITLE OF MEMBERSHIP

Associates can use the honored title of membership. The "AMRC" is an honored title which is accorded to a person's name viz. Dr. John E. Hall, Ph.D., AMRC or William Walldroff, M.S., AMRC.

Career

Credibility

Exclusive

Reputation

#### RECOGNITION ON THE PLATFORM

#### BETTER VISIBILITY AND CITATION

All the Associate members of AMRC get a badge of "Leading Member of Global Journals" on the Research Community that distinguishes them from others. Additionally, the profile is also partially maintained by our team for better visibility and citation.

Career

Credibility

Reputation



#### **FUTURE WORK**

#### GET DISCOUNTS ON THE FUTURE PUBLICATIONS

Associates receive discounts on future publications with Global Journals up to 30%. Through our recommendation programs, members also receive discounts on publications made with OARS affiliated organizations.

Career

Financial



#### GJ ACCOUNT

#### Unlimited forward of Emails

Associates get secure and fast GJ work emails with 5GB forward of emails that they may use them as their primary email. For example, john [AT] globaljournals [DOT] org.

Career

Credibility

Reputation



#### PREMIUM TOOLS

#### ACCESS TO ALL THE PREMIUM TOOLS

To take future researches to the zenith, fellows receive access to almost all the premium tools that Global Journals have to offer along with the partnership with some of the best marketing leading tools out there.

Financial

#### **CONFERENCES & EVENTS**

#### ORGANIZE SEMINAR/CONFERENCE

Associates are authorized to organize symposium/seminar/conference on behalf of Global Journal Incorporation (USA). They can also participate in the same organized by another institution as representative of Global Journal. In both the cases, it is mandatory for him to discuss with us and obtain our consent. Additionally, they get free research conferences (and others) alerts.

Career

Credibility

Financial

#### **EARLY INVITATIONS**

#### EARLY INVITATIONS TO ALL THE SYMPOSIUMS, SEMINARS, CONFERENCES

All associates receive the early invitations to all the symposiums, seminars, conferences and webinars hosted by Global Journals in their subject.

Exclusive





## Publishing Articles & Books

#### EARN 60% OF SALES PROCEEDS

Associates can publish articles (limited) without any fees. Also, they can earn up to 30-40% of sales proceeds from the sale of reference/review books/literature/publishing of research paper

Exclusive

Financial

### REVIEWERS

#### GET A REMUNERATION OF 15% OF AUTHOR FEES

Associate members are eligible to join as a paid peer reviewer at Global Journals Incorporation (USA) and can get a remuneration of 15% of author fees, taken from the author of a respective paper.

Financial

#### AND MUCH MORE

#### GET ACCESS TO SCIENTIFIC MUSEUMS AND OBSERVATORIES ACROSS THE GLOBE

All members get access to 2 selected scientific museums and observatories across the globe. All researches published with Global Journals will be kept under deep archival facilities across regions for future protections and disaster recovery. They get 5 GB free secure cloud access for storing research files.



| Associate   | Fellow  | Research Group  | BASIC                      |
|---|---|---|----------------------------|
| \$4800<br>lifetime designation  | \$6800<br>lifetime designation  | \$12500.00 organizational   | APC per article            |
| Certificate, LoR and Momento 2 discounted publishing/year Gradation of Research 10 research contacts/day 1 GB Cloud Storage GJ Community Access | Certificate, LoR and Momento Unlimited discounted publishing/year Gradation of Research Unlimited research contacts/day 5 GB Cloud Storage Online Presense Assistance GJ Community Access | Certificates, LoRs and Momentos Unlimited free publishing/year Gradation of Research Unlimited research contacts/day Unlimited Cloud Storage Online Presense Assistance GJ Community Access | <b>GJ</b> Community Access |

#### Preferred Author Guidelines

#### We accept the manuscript submissions in any standard (generic) format.

We typeset manuscripts using advanced typesetting tools like Adobe In Design, CorelDraw, TeXnicCenter, and TeXStudio. We usually recommend authors submit their research using any standard format they are comfortable with, and let Global Journals do the rest.

Alternatively, you can download our basic template from https://globaljournals.org/Template

Authors should submit their complete paper/article, including text illustrations, graphics, conclusions, artwork, and tables. Authors who are not able to submit manuscript using the form above can email the manuscript department at submit@globaljournals.org or get in touch with chiefeditor@globaljournals.org if they wish to send the abstract before submission.

#### Before and During Submission

Authors must ensure the information provided during the submission of a paper is authentic. Please go through the following checklist before submitting:

- 1. Authors must go through the complete author guideline and understand and *agree to Global Journals' ethics and code of conduct,* along with author responsibilities.
- 2. Authors must accept the privacy policy, terms, and conditions of Global Journals.
- 3. Ensure corresponding author's email address and postal address are accurate and reachable.
- 4. Manuscript to be submitted must include keywords, an abstract, a paper title, co-author(s') names and details (email address, name, phone number, and institution), figures and illustrations in vector format including appropriate captions, tables, including titles and footnotes, a conclusion, results, acknowledgments and references.
- 5. Authors should submit paper in a ZIP archive if any supplementary files are required along with the paper.
- 6. Proper permissions must be acquired for the use of any copyrighted material.
- 7. Manuscript submitted *must not have been submitted or published elsewhere* and all authors must be aware of the submission.

#### **Declaration of Conflicts of Interest**

It is required for authors to declare all financial, institutional, and personal relationships with other individuals and organizations that could influence (bias) their research.

#### Policy on Plagiarism

Plagiarism is not acceptable in Global Journals submissions at all.

Plagiarized content will not be considered for publication. We reserve the right to inform authors' institutions about plagiarism detected either before or after publication. If plagiarism is identified, we will follow COPE guidelines:

Authors are solely responsible for all the plagiarism that is found. The author must not fabricate, falsify or plagiarize existing research data. The following, if copied, will be considered plagiarism:

- Words (language)
- Ideas
- Findings
- Writings
- Diagrams
- Graphs
- Illustrations
- Lectures



- Printed material
- Graphic representations
- Computer programs
- Electronic material
- Any other original work

#### AUTHORSHIP POLICIES

Global Journals follows the definition of authorship set up by the Open Association of Research Society, USA. According to its guidelines, authorship criteria must be based on:

- 1. Substantial contributions to the conception and acquisition of data, analysis, and interpretation of findings.
- Drafting the paper and revising it critically regarding important academic content.
- 3. Final approval of the version of the paper to be published.

#### **Changes in Authorship**

The corresponding author should mention the name and complete details of all co-authors during submission and in manuscript. We support addition, rearrangement, manipulation, and deletions in authors list till the early view publication of the journal. We expect that corresponding author will notify all co-authors of submission. We follow COPE guidelines for changes in authorship.

#### Copyright

During submission of the manuscript, the author is confirming an exclusive license agreement with Global Journals which gives Global Journals the authority to reproduce, reuse, and republish authors' research. We also believe in flexible copyright terms where copyright may remain with authors/employers/institutions as well. Contact your editor after acceptance to choose your copyright policy. You may follow this form for copyright transfers.

#### **Appealing Decisions**

Unless specified in the notification, the Editorial Board's decision on publication of the paper is final and cannot be appealed before making the major change in the manuscript.

#### **Acknowledgments**

Contributors to the research other than authors credited should be mentioned in Acknowledgments. The source of funding for the research can be included. Suppliers of resources may be mentioned along with their addresses.

#### **Declaration of funding sources**

Global Journals is in partnership with various universities, laboratories, and other institutions worldwide in the research domain. Authors are requested to disclose their source of funding during every stage of their research, such as making analysis, performing laboratory operations, computing data, and using institutional resources, from writing an article to its submission. This will also help authors to get reimbursements by requesting an open access publication letter from Global Journals and submitting to the respective funding source.

#### Preparing your Manuscript

Authors can submit papers and articles in an acceptable file format: MS Word (doc, docx), LaTeX (.tex, .zip or .rar including all of your files), Adobe PDF (.pdf), rich text format (.rtf), simple text document (.txt), Open Document Text (.odt), and Apple Pages (.pages). Our professional layout editors will format the entire paper according to our official guidelines. This is one of the highlights of publishing with Global Journals—authors should not be concerned about the formatting of their paper. Global Journals accepts articles and manuscripts in every major language, be it Spanish, Chinese, Japanese, Portuguese, Russian, French, German, Dutch, Italian, Greek, or any other national language, but the title, subtitle, and abstract should be in English. This will facilitate indexing and the pre-peer review process.

The following is the official style and template developed for publication of a research paper. Authors are not required to follow this style during the submission of the paper. It is just for reference purposes.



#### Manuscript Style Instruction (Optional)

- Microsoft Word Document Setting Instructions.
- Font type of all text should be Swis721 Lt BT.
- Page size: 8.27" x 11'", left margin: 0.65, right margin: 0.65, bottom margin: 0.75.
- Paper title should be in one column of font size 24.
- Author name in font size of 11 in one column.
- Abstract: font size 9 with the word "Abstract" in bold italics.
- Main text: font size 10 with two justified columns.
- Two columns with equal column width of 3.38 and spacing of 0.2.
- First character must be three lines drop-capped.
- The paragraph before spacing of 1 pt and after of 0 pt.
- Line spacing of 1 pt.
- Large images must be in one column.
- The names of first main headings (Heading 1) must be in Roman font, capital letters, and font size of 10.
- The names of second main headings (Heading 2) must not include numbers and must be in italics with a font size of 10.

#### Structure and Format of Manuscript

The recommended size of an original research paper is under 15,000 words and review papers under 7,000 words. Research articles should be less than 10,000 words. Research papers are usually longer than review papers. Review papers are reports of significant research (typically less than 7,000 words, including tables, figures, and references)

A research paper must include:

- a) A title which should be relevant to the theme of the paper.
- b) A summary, known as an abstract (less than 150 words), containing the major results and conclusions.
- c) Up to 10 keywords that precisely identify the paper's subject, purpose, and focus.
- d) An introduction, giving fundamental background objectives.
- e) Resources and techniques with sufficient complete experimental details (wherever possible by reference) to permit repetition, sources of information must be given, and numerical methods must be specified by reference.
- Results which should be presented concisely by well-designed tables and figures.
- g) Suitable statistical data should also be given.
- h) All data must have been gathered with attention to numerical detail in the planning stage.

Design has been recognized to be essential to experiments for a considerable time, and the editor has decided that any paper that appears not to have adequate numerical treatments of the data will be returned unrefereed.

- i) Discussion should cover implications and consequences and not just recapitulate the results; conclusions should also be summarized.
- j) There should be brief acknowledgments.
- k) There ought to be references in the conventional format. Global Journals recommends APA format.

Authors should carefully consider the preparation of papers to ensure that they communicate effectively. Papers are much more likely to be accepted if they are carefully designed and laid out, contain few or no errors, are summarizing, and follow instructions. They will also be published with much fewer delays than those that require much technical and editorial correction.

The Editorial Board reserves the right to make literary corrections and suggestions to improve brevity.



#### FORMAT STRUCTURE

It is necessary that authors take care in submitting a manuscript that is written in simple language and adheres to published guidelines.

All manuscripts submitted to Global Journals should include:

#### Title

The title page must carry an informative title that reflects the content, a running title (less than 45 characters together with spaces), names of the authors and co-authors, and the place(s) where the work was carried out.

#### **Author details**

The full postal address of any related author(s) must be specified.

#### **Abstract**

The abstract is the foundation of the research paper. It should be clear and concise and must contain the objective of the paper and inferences drawn. It is advised to not include big mathematical equations or complicated jargon.

Many researchers searching for information online will use search engines such as Google, Yahoo or others. By optimizing your paper for search engines, you will amplify the chance of someone finding it. In turn, this will make it more likely to be viewed and cited in further works. Global Journals has compiled these guidelines to facilitate you to maximize the webfriendliness of the most public part of your paper.

#### Keywords

A major lynchpin of research work for the writing of research papers is the keyword search, which one will employ to find both library and internet resources. Up to eleven keywords or very brief phrases have to be given to help data retrieval, mining, and indexing.

One must be persistent and creative in using keywords. An effective keyword search requires a strategy: planning of a list of possible keywords and phrases to try.

Choice of the main keywords is the first tool of writing a research paper. Research paper writing is an art. Keyword search should be as strategic as possible.

One should start brainstorming lists of potential keywords before even beginning searching. Think about the most important concepts related to research work. Ask, "What words would a source have to include to be truly valuable in a research paper?" Then consider synonyms for the important words.

It may take the discovery of only one important paper to steer in the right keyword direction because, in most databases, the keywords under which a research paper is abstracted are listed with the paper.

#### **Numerical Methods**

Numerical methods used should be transparent and, where appropriate, supported by references.

#### **Abbreviations**

Authors must list all the abbreviations used in the paper at the end of the paper or in a separate table before using them.

#### Formulas and equations

Authors are advised to submit any mathematical equation using either MathJax, KaTeX, or LaTeX, or in a very high-quality image.

#### **Tables, Figures, and Figure Legends**

Tables: Tables should be cautiously designed, uncrowned, and include only essential data. Each must have an Arabic number, e.g., Table 4, a self-explanatory caption, and be on a separate sheet. Authors must submit tables in an editable format and not as images. References to these tables (if any) must be mentioned accurately.



#### **Figures**

Figures are supposed to be submitted as separate files. Always include a citation in the text for each figure using Arabic numbers, e.g., Fig. 4. Artwork must be submitted online in vector electronic form or by emailing it.

#### Preparation of Eletronic Figures for Publication

Although low-quality images are sufficient for review purposes, print publication requires high-quality images to prevent the final product being blurred or fuzzy. Submit (possibly by e-mail) EPS (line art) or TIFF (halftone/ photographs) files only. MS PowerPoint and Word Graphics are unsuitable for printed pictures. Avoid using pixel-oriented software. Scans (TIFF only) should have a resolution of at least 350 dpi (halftone) or 700 to 1100 dpi (line drawings). Please give the data for figures in black and white or submit a Color Work Agreement form. EPS files must be saved with fonts embedded (and with a TIFF preview, if possible).

For scanned images, the scanning resolution at final image size ought to be as follows to ensure good reproduction: line art: >650 dpi; halftones (including gel photographs): >350 dpi; figures containing both halftone and line images: >650 dpi.

Color charges: Authors are advised to pay the full cost for the reproduction of their color artwork. Hence, please note that if there is color artwork in your manuscript when it is accepted for publication, we would require you to complete and return a Color Work Agreement form before your paper can be published. Also, you can email your editor to remove the color fee after acceptance of the paper.

#### TIPS FOR WRITING A GOOD QUALITY MEDICAL RESEARCH PAPER

- 1. Choosing the topic: In most cases, the topic is selected by the interests of the author, but it can also be suggested by the guides. You can have several topics, and then judge which you are most comfortable with. This may be done by asking several questions of yourself, like "Will I be able to carry out a search in this area? Will I find all necessary resources to accomplish the search? Will I be able to find all information in this field area?" If the answer to this type of question is "yes," then you ought to choose that topic. In most cases, you may have to conduct surveys and visit several places. Also, you might have to do a lot of work to find all the rises and falls of the various data on that subject. Sometimes, detailed information plays a vital role, instead of short information. Evaluators are human: The first thing to remember is that evaluators are also human beings. They are not only meant for rejecting a paper. They are here to evaluate your paper. So present your best aspect.
- 2. Think like evaluators: If you are in confusion or getting demotivated because your paper may not be accepted by the evaluators, then think, and try to evaluate your paper like an evaluator. Try to understand what an evaluator wants in your research paper, and you will automatically have your answer. Make blueprints of paper: The outline is the plan or framework that will help you to arrange your thoughts. It will make your paper logical. But remember that all points of your outline must be related to the topic you have chosen.
- **3.** Ask your guides: If you are having any difficulty with your research, then do not hesitate to share your difficulty with your guide (if you have one). They will surely help you out and resolve your doubts. If you can't clarify what exactly you require for your work, then ask your supervisor to help you with an alternative. He or she might also provide you with a list of essential readings.
- **4.** Use of computer is recommended: As you are doing research in the field of medical research then this point is quite obvious. Use right software: Always use good quality software packages. If you are not capable of judging good software, then you can lose the quality of your paper unknowingly. There are various programs available to help you which you can get through the internet.
- 5. Use the internet for help: An excellent start for your paper is using Google. It is a wondrous search engine, where you can have your doubts resolved. You may also read some answers for the frequent question of how to write your research paper or find a model research paper. You can download books from the internet. If you have all the required books, place importance on reading, selecting, and analyzing the specified information. Then sketch out your research paper. Use big pictures: You may use encyclopedias like Wikipedia to get pictures with the best resolution. At Global Journals, you should strictly follow here.



- 6. Bookmarks are useful: When you read any book or magazine, you generally use bookmarks, right? It is a good habit which helps to not lose your continuity. You should always use bookmarks while searching on the internet also, which will make your search easier.
- 7. Revise what you wrote: When you write anything, always read it, summarize it, and then finalize it.
- 8. Make every effort: Make every effort to mention what you are going to write in your paper. That means always have a good start. Try to mention everything in the introduction—what is the need for a particular research paper. Polish your work with good writing skills and always give an evaluator what he wants. Make backups: When you are going to do any important thing like making a research paper, you should always have backup copies of it either on your computer or on paper. This protects you from losing any portion of your important data.
- **9. Produce good diagrams of your own:** Always try to include good charts or diagrams in your paper to improve quality. Using several unnecessary diagrams will degrade the quality of your paper by creating a hodgepodge. So always try to include diagrams which were made by you to improve the readability of your paper. Use of direct quotes: When you do research relevant to literature, history, or current affairs, then use of quotes becomes essential, but if the study is relevant to science, use of quotes is not preferable.
- **10.** Use proper verb tense: Use proper verb tenses in your paper. Use past tense to present those events that have happened. Use present tense to indicate events that are going on. Use future tense to indicate events that will happen in the future. Use of wrong tenses will confuse the evaluator. Avoid sentences that are incomplete.
- 11. Pick a good study spot: Always try to pick a spot for your research which is quiet. Not every spot is good for studying.
- 12. Know what you know: Always try to know what you know by making objectives, otherwise you will be confused and unable to achieve your target.
- **13.** Use good grammar: Always use good grammar and words that will have a positive impact on the evaluator; use of good vocabulary does not mean using tough words which the evaluator has to find in a dictionary. Do not fragment sentences. Eliminate one-word sentences. Do not ever use a big word when a smaller one would suffice.

Verbs have to be in agreement with their subjects. In a research paper, do not start sentences with conjunctions or finish them with prepositions. When writing formally, it is advisable to never split an infinitive because someone will (wrongly) complain. Avoid clichés like a disease. Always shun irritating alliteration. Use language which is simple and straightforward. Put together a neat summary.

- **14. Arrangement of information:** Each section of the main body should start with an opening sentence, and there should be a changeover at the end of the section. Give only valid and powerful arguments for your topic. You may also maintain your arguments with records.
- **15. Never start at the last minute:** Always allow enough time for research work. Leaving everything to the last minute will degrade your paper and spoil your work.
- **16. Multitasking in research is not good:** Doing several things at the same time is a bad habit in the case of research activity. Research is an area where everything has a particular time slot. Divide your research work into parts, and do a particular part in a particular time slot.
- 17. Never copy others' work: Never copy others' work and give it your name because if the evaluator has seen it anywhere, you will be in trouble. Take proper rest and food: No matter how many hours you spend on your research activity, if you are not taking care of your health, then all your efforts will have been in vain. For quality research, take proper rest and food.
- 18. Go to seminars: Attend seminars if the topic is relevant to your research area. Utilize all your resources.
- 19. Refresh your mind after intervals: Try to give your mind a rest by listening to soft music or sleeping in intervals. This will also improve your memory. Acquire colleagues: Always try to acquire colleagues. No matter how sharp you are, if you acquire colleagues, they can give you ideas which will be helpful to your research.



- **20.** Think technically: Always think technically. If anything happens, search for its reasons, benefits, and demerits. Think and then print: When you go to print your paper, check that tables are not split, headings are not detached from their descriptions, and page sequence is maintained.
- 21. Adding unnecessary information: Do not add unnecessary information like "I have used MS Excel to draw graphs." Irrelevant and inappropriate material is superfluous. Foreign terminology and phrases are not apropos. One should never take a broad view. Analogy is like feathers on a snake. Use words properly, regardless of how others use them. Remove quotations. Puns are for kids, not grunt readers. Never oversimplify: When adding material to your research paper, never go for oversimplification; this will definitely irritate the evaluator. Be specific. Never use rhythmic redundancies. Contractions shouldn't be used in a research paper. Comparisons are as terrible as clichés. Give up ampersands, abbreviations, and so on. Remove commas that are not necessary. Parenthetical words should be between brackets or commas. Understatement is always the best way to put forward earth-shaking thoughts. Give a detailed literary review.
- **22.** Report concluded results: Use concluded results. From raw data, filter the results, and then conclude your studies based on measurements and observations taken. An appropriate number of decimal places should be used. Parenthetical remarks are prohibited here. Proofread carefully at the final stage. At the end, give an outline to your arguments. Spot perspectives of further study of the subject. Justify your conclusion at the bottom sufficiently, which will probably include examples.
- **23. Upon conclusion:** Once you have concluded your research, the next most important step is to present your findings. Presentation is extremely important as it is the definite medium though which your research is going to be in print for the rest of the crowd. Care should be taken to categorize your thoughts well and present them in a logical and neat manner. A good quality research paper format is essential because it serves to highlight your research paper and bring to light all necessary aspects of your research.

#### INFORMAL GUIDELINES OF RESEARCH PAPER WRITING

#### Key points to remember:

- Submit all work in its final form.
- Write your paper in the form which is presented in the guidelines using the template.
- Please note the criteria peer reviewers will use for grading the final paper.

#### **Final points:**

One purpose of organizing a research paper is to let people interpret your efforts selectively. The journal requires the following sections, submitted in the order listed, with each section starting on a new page:

The introduction: This will be compiled from reference matter and reflect the design processes or outline of basis that directed you to make a study. As you carry out the process of study, the method and process section will be constructed like that. The results segment will show related statistics in nearly sequential order and direct reviewers to similar intellectual paths throughout the data that you gathered to carry out your study.

#### The discussion section:

This will provide understanding of the data and projections as to the implications of the results. The use of good quality references throughout the paper will give the effort trustworthiness by representing an alertness to prior workings.

Writing a research paper is not an easy job, no matter how trouble-free the actual research or concept. Practice, excellent preparation, and controlled record-keeping are the only means to make straightforward progression.

#### General style:

Specific editorial column necessities for compliance of a manuscript will always take over from directions in these general guidelines.

To make a paper clear: Adhere to recommended page limits.



#### Mistakes to avoid:

- Insertion of a title at the foot of a page with subsequent text on the next page.
- Separating a table, chart, or figure—confine each to a single page.
- Submitting a manuscript with pages out of sequence.
- In every section of your document, use standard writing style, including articles ("a" and "the").
- Keep paying attention to the topic of the paper.
- Use paragraphs to split each significant point (excluding the abstract).
- Align the primary line of each section.
- Present your points in sound order.
- Use present tense to report well-accepted matters.
- Use past tense to describe specific results.
- Do not use familiar wording; don't address the reviewer directly. Don't use slang or superlatives.
- Avoid use of extra pictures—include only those figures essential to presenting results.

#### Title page:

Choose a revealing title. It should be short and include the name(s) and address(es) of all authors. It should not have acronyms or abbreviations or exceed two printed lines.

**Abstract:** This summary should be two hundred words or less. It should clearly and briefly explain the key findings reported in the manuscript and must have precise statistics. It should not have acronyms or abbreviations. It should be logical in itself. Do not cite references at this point.

An abstract is a brief, distinct paragraph summary of finished work or work in development. In a minute or less, a reviewer can be taught the foundation behind the study, common approaches to the problem, relevant results, and significant conclusions or new questions.

Write your summary when your paper is completed because how can you write the summary of anything which is not yet written? Wealth of terminology is very essential in abstract. Use comprehensive sentences, and do not sacrifice readability for brevity; you can maintain it succinctly by phrasing sentences so that they provide more than a lone rationale. The author can at this moment go straight to shortening the outcome. Sum up the study with the subsequent elements in any summary. Try to limit the initial two items to no more than one line each.

Reason for writing the article—theory, overall issue, purpose.

- Fundamental goal.
- To-the-point depiction of the research.
- Consequences, including definite statistics—if the consequences are quantitative in nature, account for this; results of any numerical analysis should be reported. Significant conclusions or questions that emerge from the research.

#### Approach:

- Single section and succinct.
- An outline of the job done is always written in past tense.
- o Concentrate on shortening results—limit background information to a verdict or two.
- Exact spelling, clarity of sentences and phrases, and appropriate reporting of quantities (proper units, important statistics) are just as significant in an abstract as they are anywhere else.

#### Introduction:

The introduction should "introduce" the manuscript. The reviewer should be presented with sufficient background information to be capable of comprehending and calculating the purpose of your study without having to refer to other works. The basis for the study should be offered. Give the most important references, but avoid making a comprehensive appraisal of the topic. Describe the problem visibly. If the problem is not acknowledged in a logical, reasonable way, the reviewer will give no attention to your results. Speak in common terms about techniques used to explain the problem, if needed, but do not present any particulars about the protocols here.



The following approach can create a valuable beginning:

- o Explain the value (significance) of the study.
- o Defend the model—why did you employ this particular system or method? What is its compensation? Remark upon its appropriateness from an abstract point of view as well as pointing out sensible reasons for using it.
- Present a justification. State your particular theory(-ies) or aim(s), and describe the logic that led you to choose them.
- Briefly explain the study's tentative purpose and how it meets the declared objectives.

#### Approach:

Use past tense except for when referring to recognized facts. After all, the manuscript will be submitted after the entire job is done. Sort out your thoughts; manufacture one key point for every section. If you make the four points listed above, you will need at least four paragraphs. Present surrounding information only when it is necessary to support a situation. The reviewer does not desire to read everything you know about a topic. Shape the theory specifically—do not take a broad view.

As always, give awareness to spelling, simplicity, and correctness of sentences and phrases.

#### Procedures (methods and materials):

This part is supposed to be the easiest to carve if you have good skills. A soundly written procedures segment allows a capable scientist to replicate your results. Present precise information about your supplies. The suppliers and clarity of reagents can be helpful bits of information. Present methods in sequential order, but linked methodologies can be grouped as a segment. Be concise when relating the protocols. Attempt to give the least amount of information that would permit another capable scientist to replicate your outcome, but be cautious that vital information is integrated. The use of subheadings is suggested and ought to be synchronized with the results section.

When a technique is used that has been well-described in another section, mention the specific item describing the way, but draw the basic principle while stating the situation. The purpose is to show all particular resources and broad procedures so that another person may use some or all of the methods in one more study or referee the scientific value of your work. It is not to be a step-by-step report of the whole thing you did, nor is a methods section a set of orders.

#### **Materials:**

Materials may be reported in part of a section or else they may be recognized along with your measures.

#### Methods:

- Report the method and not the particulars of each process that engaged the same methodology.
- Describe the method entirely.
- o To be succinct, present methods under headings dedicated to specific dealings or groups of measures.
- Simplify—detail how procedures were completed, not how they were performed on a particular day.
- o If well-known procedures were used, account for the procedure by name, possibly with a reference, and that's all.

#### Approach:

It is embarrassing to use vigorous voice when documenting methods without using first person, which would focus the reviewer's interest on the researcher rather than the job. As a result, when writing up the methods, most authors use third person passive voice.

Use standard style in this and every other part of the paper—avoid familiar lists, and use full sentences.

#### What to keep away from:

- o Resources and methods are not a set of information.
- o Skip all descriptive information and surroundings—save it for the argument.
- o Leave out information that is immaterial to a third party.



#### **Results:**

The principle of a results segment is to present and demonstrate your conclusion. Create this part as entirely objective details of the outcome, and save all understanding for the discussion.

The page length of this segment is set by the sum and types of data to be reported. Use statistics and tables, if suitable, to present consequences most efficiently.

You must clearly differentiate material which would usually be incorporated in a study editorial from any unprocessed data or additional appendix matter that would not be available. In fact, such matters should not be submitted at all except if requested by the instructor.

#### **Content:**

- Sum up your conclusions in text and demonstrate them, if suitable, with figures and tables.
- o In the manuscript, explain each of your consequences, and point the reader to remarks that are most appropriate.
- o Present a background, such as by describing the question that was addressed by creation of an exacting study.
- Explain results of control experiments and give remarks that are not accessible in a prescribed figure or table, if appropriate.
- Examine your data, then prepare the analyzed (transformed) data in the form of a figure (graph), table, or manuscript.

#### What to stay away from:

- Do not discuss or infer your outcome, report surrounding information, or try to explain anything.
- Do not include raw data or intermediate calculations in a research manuscript.
- o Do not present similar data more than once.
- o A manuscript should complement any figures or tables, not duplicate information.
- Never confuse figures with tables—there is a difference.

#### Approach:

As always, use past tense when you submit your results, and put the whole thing in a reasonable order.

Put figures and tables, appropriately numbered, in order at the end of the report.

If you desire, you may place your figures and tables properly within the text of your results section.

#### Figures and tables:

If you put figures and tables at the end of some details, make certain that they are visibly distinguished from any attached appendix materials, such as raw facts. Whatever the position, each table must be titled, numbered one after the other, and include a heading. All figures and tables must be divided from the text.

#### Discussion:

The discussion is expected to be the trickiest segment to write. A lot of papers submitted to the journal are discarded based on problems with the discussion. There is no rule for how long an argument should be.

Position your understanding of the outcome visibly to lead the reviewer through your conclusions, and then finish the paper with a summing up of the implications of the study. The purpose here is to offer an understanding of your results and support all of your conclusions, using facts from your research and generally accepted information, if suitable. The implication of results should be fully described.

Infer your data in the conversation in suitable depth. This means that when you clarify an observable fact, you must explain mechanisms that may account for the observation. If your results vary from your prospect, make clear why that may have happened. If your results agree, then explain the theory that the proof supported. It is never suitable to just state that the data approved the prospect, and let it drop at that. Make a decision as to whether each premise is supported or discarded or if you cannot make a conclusion with assurance. Do not just dismiss a study or part of a study as "uncertain."



Research papers are not acknowledged if the work is imperfect. Draw what conclusions you can based upon the results that you have, and take care of the study as a finished work.

- o You may propose future guidelines, such as how an experiment might be personalized to accomplish a new idea.
- o Give details of all of your remarks as much as possible, focusing on mechanisms.
- Make a decision as to whether the tentative design sufficiently addressed the theory and whether or not it was correctly restricted. Try to present substitute explanations if they are sensible alternatives.
- One piece of research will not counter an overall question, so maintain the large picture in mind. Where do you go next? The best studies unlock new avenues of study. What questions remain?
- o Recommendations for detailed papers will offer supplementary suggestions.

#### Approach:

When you refer to information, differentiate data generated by your own studies from other available information. Present work done by specific persons (including you) in past tense.

Describe generally acknowledged facts and main beliefs in present tense.

#### THE ADMINISTRATION RULES

Administration Rules to Be Strictly Followed before Submitting Your Research Paper to Global Journals Inc.

Please read the following rules and regulations carefully before submitting your research paper to Global Journals Inc. to avoid rejection.

Segment draft and final research paper: You have to strictly follow the template of a research paper, failing which your paper may get rejected. You are expected to write each part of the paper wholly on your own. The peer reviewers need to identify your own perspective of the concepts in your own terms. Please do not extract straight from any other source, and do not rephrase someone else's analysis. Do not allow anyone else to proofread your manuscript.

Written material: You may discuss this with your guides and key sources. Do not copy anyone else's paper, even if this is only imitation, otherwise it will be rejected on the grounds of plagiarism, which is illegal. Various methods to avoid plagiarism are strictly applied by us to every paper, and, if found guilty, you may be blacklisted, which could affect your career adversely. To guard yourself and others from possible illegal use, please do not permit anyone to use or even read your paper and file.



## CRITERION FOR GRADING A RESEARCH PAPER (COMPILATION) BY GLOBAL JOURNALS

Please note that following table is only a Grading of "Paper Compilation" and not on "Performed/Stated Research" whose grading solely depends on Individual Assigned Peer Reviewer and Editorial Board Member. These can be available only on request and after decision of Paper. This report will be the property of Global Journals.

| Topics                    | Grades   |   |   |
|---------------------------|--|---|---|
|                           |  |   |   |
|                           | A-B  | C-D   | E-F   |
| Abstract                  | Clear and concise with appropriate content, Correct format. 200 words or below   | Unclear summary and no<br>specific data, Incorrect form<br>Above 200 words                          | No specific data with ambiguous information Above 250 words   |
| Introduction              | Containing all background details with clear goal and appropriate details, flow specification, no grammar and spelling mistake, well organized sentence and paragraph, reference cited | Unclear and confusing data, appropriate format, grammar and spelling errors with unorganized matter | Out of place depth and content, hazy format                   |
| Methods and<br>Procedures | Clear and to the point with well arranged paragraph, precision and accuracy of facts and figures, well organized subheads  | Difficult to comprehend with<br>embarrassed text, too much<br>explanation but completed             | Incorrect and unorganized structure with hazy meaning         |
| Result                    | Well organized, Clear and specific, Correct units with precision, correct data, well structuring of paragraph, no grammar and spelling mistake   | Complete and embarrassed text, difficult to comprehend  | Irregular format with wrong facts and figures                 |
| Discussion                | Well organized, meaningful specification, sound conclusion, logical and concise explanation, highly structured paragraph reference cited   | Wordy, unclear conclusion, spurious   | Conclusion is not cited, unorganized, difficult to comprehend |
| References                | Complete and correct format, well organized  | Beside the point, Incomplete  | Wrong format and structuring                                  |



## INDEX

#### A

 $\begin{array}{l} \text{Alveolar} \cdot 10 \\ \text{Amalgam} \cdot 1, 2, 3, 4, 5, 6, 7 \\ \text{Assertion} \cdot 2 \\ \text{Astonishing} \cdot 3 \end{array}$ 

#### D

 $\begin{array}{l} \text{Dimorphism} \cdot 9,\, 14,\, 15 \\ \text{Dissemination} \cdot 23 \end{array}$ Distorted · 10  $\text{Distortion} \cdot 9$ 

Integrative · 3

#### Μ

Magnification · 9 Mandible · 8, 9, 10, 12, 14, 15, 20, 21

### P

Panoramic · 9, 14, 15 Protruding · 10



# Global Journal of Medical Research

Visit us on the Web at www.GlobalJournals.org | www.MedicalResearchJournal.org or email us at helpdesk@globaljournals.org

70116 58698

61427>

122N 9755896